

List of excluded studies and reasons for exclusion

Table Excluded studies and reasons for exclusion (n=748)

Reference	Reason for exclusion
Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. <i>The Lancet Neurology</i> 2009; 8 (7):613-8	Not a disease modification trial
AbbVie. NCT02573740 Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment. URL: https://clinicaltrials.gov/ct2/show/NCT02573740 Accessed 29th January 2016	No quantitative outcome relating to disease modification
Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease. <i>Neurology</i> 2001; 57 (8):1515-7	Not a disease modification trial
Adami M, Scarpini E, Bruno G, Zappala G, Richarz U, Gaudig M, et al. Cessation versus continuation of 12 months galantamine therapy in patients with Lzheimer's disease: A randomised, double blind, placebo controlled withdrawal trial. <i>Alzheimers Dement</i> 2011; 1 :S794	Not published in a peer reviewed journal article or an ongoing trial
Adamus WS, Leonard JP, Tröger W. Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease. <i>Life sciences</i> 1995; 56 (11):883-90	No participants with mild or moderate dementia
Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. <i>Current Therapeutic Research - Clinical and Experimental</i> 1998; 59 (12):837-45	Not a disease modification trial
Aguglia E, Onor ML, Saina M, Maso E. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. <i>Current medical research and opinion</i> 2004; 20 (11):1747-52	Not a disease modification trial
Aguiar P, Monteiro L, Feres A, Gomes I, Melo A. Rivastigmine transdermal patch and physical exercises for Alzheimer's disease: a randomized clinical trial. <i>Current Alzheimer Research</i> 2014; 11 (6):532-7	Not a disease modification trial
Aguirre E, Spector A, Hoe J, Russell IT, Knapp M, Woods RT, et al. Maintenance Cognitive Stimulation Therapy (CST) for dementia: a single-blind, multi-centre, randomized controlled trial of Maintenance CST vs. CST for dementia. <i>Trials</i> 2010; 11 :46	Not a disease modification trial
Ahlin A, Nyback H, Junthe T, Ohman G, Nordgren I. Tetrahydroaminoacridine in Alzheimer's dementia: Clinical and biochemical results of a double-blind crossover trial. <i>Human Psychopharmacology</i> 1991; 6 (2):109-18	Not a disease modification trial
Ahmed MA, Darwish ES, Khedr EM, El Serogy YM, Ali AM. Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer's dementia. <i>Journal of Neurology</i> 2012; 259 (1):83-92	Not a disease modification trial

Reference	Reason for exclusion
Akanuma K, Meguro K, Meguro M, Sasaki E, Chiba K, Ishii H, et al. Improved social interaction and increased anterior cingulate metabolism after group reminiscence with reality orientation approach for vascular dementia. <i>Psychiatry Research</i> 2011; 192 (3):183-7	Not a disease modification trial
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> 2003; 74 (7):863-6	Not a disease modification trial
Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. <i>Journal of Clinical Pharmacy & Therapeutics</i> 2003; 28 (1):53-9	Not a disease modification trial
Alva G, Grossberg GT, Schmitt FA, Meng X, Olin JT. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. <i>International Journal of Geriatric Psychiatry</i> 2011; 26 (4):356-63	Not a disease modification trial
Alva G, Isaacson R, Sadowsky C, Grossberg G, Meng X, Somogyi M. Efficacy of higher-dose 13.3 mg/24 h (15 cm ²) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: Domain and individual item analysis. <i>International journal of geriatric psychiatry</i> 2014; 29 (9):920-7	Not a disease modification trial
Alvarez XA, Cacabelos R, Sampedro C, Couceiro V, Alexandre M, Vargas M, et al. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil. <i>Current Alzheimer research</i> 2011; 8 (5):583-91	Not a disease modification trial
Alvarez A, Iglesias O, Alexandre M, Linares C, Figueroa J, Muresanu D, et al. Cerebrolysin and combination therapy enhance serum bdnf in ad patients. <i>Alzheimer's & dementia</i> 2014; 10 :774	Not published in a peer reviewed journal article or an ongoing trial
Amenta F, Carotenuto A, Fasanaro AM, Rea R, Traini E. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alfoscerate in Alzheimer's disease with cerebrovascular injury: interim results. <i>Journal of the neurological sciences</i> 2012; 322 (1-2):96-101	Not a disease modification trial
Amici S, Lanari A, Romani R, Antognelli C, Gallai V, Parnetti L. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. <i>Mechanisms of Ageing and Development</i> 2001; 122 (16):2057-62	Not a disease modification trial
Amieva H, Dartigues JF. ETNA3, a clinical randomized study assessing three cognitive-oriented therapies in dementia: rationale and general design. <i>Revue Neurologique</i> 2013; 169 (10):752-6	Not a disease modification trial
Andersen F, Viitanen M, Halvorsen DS, Straume B, Wilsgaard T, Engstad TA. The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design. <i>BMC Neurology</i> 2012; 12 :59	Not a disease modification trial
Andrade LP, Gobbi LT, Coelho FG, Christofolletti G, Costa JL, Stella F. Benefits of multimodal exercise intervention for postural control and frontal cognitive	Not a disease modification trial

Reference	Reason for exclusion
functions in individuals with Alzheimer's disease: a controlled trial. <i>Journal of the American Geriatrics Society</i> 2013; 61 (11):1919-26	
Annweiler C, Herrmann FR, Fantino B, Brugg B, Beauchet O. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. <i>Cognitive and Behavioral Neurology</i> 2012 ; 25 (3):121-7	Not a randomised controlled trial/clinical controlled trial
Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain <i>European Journal of Health Economics</i> 2006; 7 (2):137-44	Not a disease modification trial
Araki T, Wake R, Miyaoka T, Kawakami K, Nagahama M, Furuya M, et al. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area. <i>International Journal of Geriatric Psychiatry</i> 2014; 29 (9):881-9	Not a disease modification trial
Arcoverde C, Deslandes A, Moraes H, Almeida C, Araujo NB, Vasques PE, et al. Treadmill training as an augmentation treatment for Alzheimer's disease: A pilot randomized controlled study. <i>Arquivos de neuro-psiquiatria</i> 2014; 72 (3):190-6	Not a disease modification trial
Arlt S, Muller-Thomsen T, Beisiegel U, Kontush A. Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer's disease. <i>Neurochemical Research</i> 2012; 37 (12):2706-14	Not a disease modification trial
Aronson S, Van Baelen B, Kavanagh S, Schwalen S. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. <i>Drugs & Aging</i> 2009; 26 (3):231-9	Not a disease modification trial
Arrigo A, Moglia A, Borsotti L. A double-blind, placebo-controlled, crossover trial with nicergoline in patients with senile dementia. <i>International Journal of Clinical Pharmacology Research</i> 1982; 2 (4 Suppl. 1):33-41	Not a disease modification trial
Ash E, Bregman N, Moore O, Korczyn A, Zangen A. Transcranial magnetic stimulation of deep brain regions in Alzheimer's disease. <i>Alzheimer's & dementia</i> 2014; 10 :P450	Not published in a peer reviewed journal article or an ongoing trial
Ash EL, Vakhapova V, Bova I, Simon E, Korem M, Eldad M, et al. Transcranial magnetic stimulation of deep brain regions in Alzheimer's disease: A pilot study. <i>Annals of Neurology</i> 2012; 72 :S126	Not published in a peer reviewed journal article or an ongoing trial
Ashford JW, Adamson M, Beale T, La D, Hernandez B, Noda A, et al. MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia. <i>Journal of Alzheimer's Disease</i> 2011; 26 (SUPPL. 3):331-6	Not a disease modification trial
Asp E, Cloutier F, Fay S, Cook C, Robertson ML, Fisk J, et al. Verbal repetition in patients with Alzheimer's disease who receive donepezil. <i>International Journal of Geriatric Psychiatry</i> 2006; 21 (5):426-31	Not a disease modification trial
Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. <i>Neurology</i> 2001; 57 (4):605-12	Not a disease modification trial

Reference	Reason for exclusion
Atri A, Hendrix S, Pejovic V, Graham S. Extended-release daily memantine provides increasing cumulative benefits across clinical domains over 24 weeks in patients with moderate to severe Alzheimer's disease: An analysis of area under the curve. <i>Neurology</i> 2014; 1	Not published in a peer reviewed journal article or an ongoing trial
Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer's disease receiving donepezil: New analyses of efficacy and safety for combination therapy. <i>Alzheimer's research & therapy</i> 2013; 5 (1)	Not a disease modification trial
Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease. <i>Alzheimer Disease & Associated Disorders</i> 2008; 22 (3):209-21	Not a disease modification trial
Auchus A, Brashear H, Salloway S, Korczyn A, De Deyn P, Gassmann-Mayer C. Galantamine treatment of vascular dementia: A randomized trial. <i>Neurology</i> 2007; 69 (5):448-58	Not a disease modification trial
Avila R, Carvalho IA, Bottino CM, Miotto EC. Neuropsychological rehabilitation in mild and moderate Alzheimer's disease patients. <i>Behavioural neurology</i> 2007; 18 (4):225-33	Not a disease modification trial
Bachynsky J, McCracken P, Lier D, Alloul K, Jacobs P. Propentofylline treatment for Alzheimer disease and vascular dementia: an economic evaluation based on functional abilities. <i>Alzheimer Disease & Associated Disorders</i> 2000; 14 (2):102-11	Not a disease modification trial
Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. <i>Journal of Alzheimer's disease</i> 2007; 11 (4):471-9	Not a disease modification trial
Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten ECW, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: The VantagE study. <i>Current Medical Research and Opinion</i> 2008; 24 (9):2561-74	Not a disease modification trial
Ban TA, Morey LC, Aguglia E, Batista R, Campanella G, Conti L, et al. Glycosaminoglycan polysulfate in the treatment of old age dementias. <i>Progress in neuro-psychopharmacology & biological psychiatry</i> 1991; 15 (3):323-42	Not a disease modification trial
Barak Y, Levine J, Glasman A, Elizur A, Belmaker RH. Inositol treatment of Alzheimer's disease: A double blind, cross-over placebo controlled trial. <i>Progress in Neuro-Psychopharmacology & Biological Psychiatry</i> 1996; 20 (4):729-36	Not a disease modification trial
Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. <i>Movement Disorders</i> 2008; 23 (11):1532-40	Not a disease modification trial
Bars PL, Kieser M, Itil KZ. A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia. <i>Dementia and geriatric cognitive disorders</i> 2000; 11 (4):230-7	Not a disease modification trial

Reference	Reason for exclusion
Batman MW. The effects of therapeutic aquatic exercise on patients with Alzheimer's Disease. (elderly) <i>Dissertation Abstracts International: Section B: The Sciences and Engineering</i> 1999; 60 (6-B):2933	Not published in a peer reviewed journal article or an ongoing trial
Battaglia A, Annon K, Pamparana F, De Paolis C, Bonura ML, Stekke W et al. P-8-11 Nicergoline in the long term treatment of mild or moderate senile dementia. A multicenter double-blind, randomized, placebo-controlled trial. <i>European Neuropsychopharmacology</i> 1995; 5 (3):383	Not published in a peer reviewed journal article or an ongoing trial
Baum L, Lam CWK, Cheung SKK, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. <i>Journal of Clinical Psychopharmacology</i> 2008; 28 (1):110-3	Not published in a peer reviewed journal article or an ongoing trial
Bayer AJ, Bokonjic R, Booya NH, Demarin V, Ersmark B, Fairbairn AF, et al. European pentoxifylline multi-infarct dementia study. <i>European Neurology</i> 1996; 36 (5):315-21	Not a disease modification trial
Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. <i>Alzheimer Disease & Associated Disorders</i> 1996; 10 (3):124-31	Not a disease modification trial
Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study. <i>Alzheimer Disease & Associated Disorders</i> 1998; 12 (1):54-7	Not a disease modification trial
Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. <i>Journal of molecular neuroscience</i> 2002; 19 (1-2):201-6	Not a disease modification trial
Beller SA, Overall JE, Swann AC. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level. <i>Psychopharmacology</i> 1985; 87 (2):147-51	Not a disease modification trial
Bentham PW. A double-blind placebo-controlled trial of L-tryptophan to assess the degree of cognitive and behavioural improvement in patients with Alzheimer-type dementia and to compare differential response in clinical sub-groups. <i>International Clinical Psychopharmacology</i> 1990; 5 (4):261-72	Not a disease modification trial
Bergamaschini LC, Scarpini E, Rossi E, Galimberti D, Case A, Lucca U, et al. [Randomised pilot study on the feasibility of Enoxaparin treatment in Alzheimer's disease]. <i>Neurodegenerative Diseases</i> 2011; 8	Full text unavailable in English
Bergamasco B, Scarzella L, La Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. <i>Functional Neurology</i> 1994; 9 (3):161-8	Not a disease modification trial
Bergamasco B, Villardita C, Coppi R. Idebenone in the treatment of multi-infarct dementia: A randomised, double-blind, placebo controlled multicentre trial. <i>Archives of Gerontology and Geriatrics</i> 1992; 15 (3):271-8	Not a disease modification trial

Reference	Reason for exclusion
Beverdorf DQ, Warner JL, Davis RA, Sharma UK, Nagaraja HN, Scharre DW. Donepezil in the treatment of Dementia with lewy bodies. <i>The American Journal of Geriatric Psychiatry</i> 2004; 12 (5):542-3	Not a disease modification trial
Bierer LM, Aisen PS, Davidson M, Ryan TM, Schmeidler J, Davis KL. A pilot study of clonidine plus physostigmine in Alzheimer's disease. <i>Dementia</i> 1994; 5 (5):243-6	Not a disease modification trial
Black RS, Barclay LL, Nolan KA, Thaler HT, Hardiman ST, Blass JP. Pentoxifylline in cerebrovascular dementia. <i>Journal of the American Geriatrics Society</i> 1992; 40 (3):237-44	Not a disease modification trial
Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. <i>Stroke</i> 2003; 34 (10):2323-30	Not a disease modification trial
Blass JP, Cyrus PA, Bieber F, Gulanski B. Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer disease. The Metrifonate Study Group. <i>Alzheimer Disease & Associated Disorders</i> 2000; 14 (1):39-45	Not a disease modification trial
Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> 2006; 16 (11):771-4	Not a disease modification trial
Blesa R, Davidson M, Kurz A, Reichman W, van Baelen B, Schwalen S Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months <i>Dementia & Geriatric Cognitive Disorders</i> 2003; 15 (2):79-87	Not a disease modification trial
Boada-Rovira M. [Human Albumin Grifols 5% in plasmapheresis: a new therapy involving beta-amyloid mobilisation in Alzheimer's disease]. <i>Revista de neurologia</i> 2010; 50 (Suppl 5):S9-18	Full text unavailable in English
Boada-Rovira M, Lopez O, Nunez L, Ortiz P, Anaya F, Hernandez I, et al. A phase II study to evaluate the efficacy and safety of plasma replacement with 5% albumin in beta-amyloid peptide clearance in cerebrospinal fluid, and its effects in patients with mild/moderate Alzheimer's disease. <i>Alzheimer's & dementia</i> 2014; 10 :P274	Not published in a peer reviewed journal article or an ongoing trial
Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. <i>Archives of neurology</i> 1997; 54 (4):465-73	Not a disease modification trial
Bogaert P, Grinsven R, Tolson D, Wouters K, Engelborghs S, Mussele S. Effects of SolCos model-based individual reminiscence on older adults with mild to moderate dementia due to Alzheimer disease: a pilot study. <i>Journal of the American Medical Directors Association</i> 2013; 14 (7):528	Not a disease modification trial
Bokde ALW, Karmann M, Teipel SJ, Born C, Lieb M, Reiser MF, et al. Decreased activation along the dorsal visual pathway after a 3-month treatment with	Not a disease modification trial

Reference	Reason for exclusion
galantamine in mild Alzheimer disease: A functional magnetic resonance imaging study. <i>Journal of Clinical Psychopharmacology</i> 2009; 29 (2):147-56	
Bottino CMC, Carvalho IAM, Alvarez AMM, Avila R, Zukauskas PR, Bustamante SEZ, et al. Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study. <i>Clinical Rehabilitation</i> 2005; 19 (8):861-9 9	Not a disease modification trial
Boxer A, Knopman D, Kaufer D, Grossman M, Onyike C, Graf-Radford N, et al. A randomized, multicenter, placebo controlled trial of memantine for behavioral variant ftd and semantic variant PPA. <i>Alzheimers Dement</i> 2012; 1 :P405	Not published in a peer reviewed journal article or an ongoing trial
Boxer A, Knopman D, Kaufer D, Grossman M, Onyike C, Graf-Radford N, et al. A 26-week, multicenter, randomized, double blind, placebo controlled trial of memantine for behavioral variant FTD and semantic variant PPA. <i>Dementia and geriatric cognitive disorders</i> 2012; 34 :47-8	Not published in a peer reviewed journal article or an ongoing trial
Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. <i>The Lancet Neurology</i> 2013; 12 (2):149-56	Not a disease modification trial
Boxer A, Tartaglia M, Koestler M, Lasky A, Fine E, Heuer H, et al. A 12 week, randomized, double-blind, placebo-controlled pilot clinical trial of davunetide 15 mg intranasally twice daily for FTLD with predicted tau pathology (CBD,PNFA, PSP). <i>Dementia and Geriatric Cognitive Disorders</i> 2010; 30 :28-9	Not published in a peer reviewed journal article or an ongoing trial
Breeze RW, Cox S, Rodgers-Cox J. Changes in P-300 latency as a result of co-dergocrine mesylate therapy in patients with senile dementia. <i>International journal of geriatric psychiatry</i> 1988; 3 (4):263-6	Not a disease modification trial
Brem A-K, Atkinson NJ, Seligson EE, Pascual-Leone A. Differential pharmacological effects on brain reactivity and plasticity in Alzheimer's disease. <i>Frontiers in Psychiatry</i> 2013; 4 :124	Not a disease modification trial
Brem AK, Schilberg L, Freitas C, Atkinson N, Seligson E, Pascual-Leone A. Effects of cognitive training and rTMS in Alzheimer's disease. <i>Alzheimers Dement</i> 2013; 1 :664	Not published in a peer reviewed journal article or an ongoing trial
Brem AK, Schilberg L, Freitas C, Atkinson N, Seligson E, Pascual-Leone A. Synergistic effects of rTMS and cognitive training in Alzheimer's Disease. <i>Journal of the Neurological Sciences</i> 2013; 333 :e343	Not published in a peer reviewed journal article or an ongoing trial
Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. <i>Dementia and geriatric cognitive disorders</i> 2005; 20 (2-3):120-32	Not a disease modification trial
Brooks JO, 3rd, Yesavage JA, Carta A, Bravi D. Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: a reanalysis of a double-blind, placebo-controlled study using the trilinear approach. <i>International Psychogeriatrics</i> 1998; 10 (2):193-203	Not a disease modification trial
Brown D, Spanjers K, Atherton N, Lowe J, Stonehewer L, Bridle C, et al. Development of an exercise intervention to improve cognition in people with	Not a disease modification trial

Reference

Reason for exclusion

mild to moderate dementia: Dementia And Physical Activity (DAPA) Trial, registration ISRCTN32612072 *Physiotherapy* 2015;**101**(2):126-34

Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. *Current Medical Research & Opinion* 2006;**22**(3):483-94

Not a disease modification trial

Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. *Current Medical Research & Opinion* 2005;**21**(8):1317-27

Not a disease modification trial

Burgener SC, Yang Y, Gilbert R, Marsh-Yant S. The effects of a multimodal intervention on outcomes of persons with early-stage dementia American. *Journal of Alzheimer's Disease & Other Dementias* 2008;**23**(4):382-94

Not a disease modification trial

Burke D. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. *ACP Journal Club* 2012;**156**(6):1

Not published in a peer reviewed journal article or an ongoing trial

Burke WJ, Ranno AE, Roccaforte WH, Wengel SP, Bayer BL, Willcockson NK. L-deprenyl in the treatment of mild dementia of the Alzheimer type: preliminary results. *Journal of the American Geriatrics Society* 1993;**41**(4):367-70

Not a disease modification trial

Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK. L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial. *Journal of the American Geriatrics Society* 1993;**41**(11):1219-25

Not a disease modification trial

Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. *Movement Disorders* 2006;**21**(11):1899-907

Not a disease modification trial

Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. *International journal of geriatric psychiatry* 2007;**22**(8):806-12

Not a disease modification trial

Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial *Dementia & Geriatric Cognitive Disorders* 1999;**10**(3):237-44

Not a disease modification trial

Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. *International Journal of Geriatric Psychiatry* 2004;**19**(3):243-9

Not a disease modification trial

Burns A GS, Perdomo C. Long-term use of donepezil may be safe and effective in elderly AD patients. *Brown University Geriatric Psychopharmacology Update* 2007;**11**(10):3-4

Not a disease modification trial

Buschert VC, Friese U, Teipel SJ, Schneider P, Merensky W, Rujescu D, et al. Effects of a newly developed cognitive intervention in amnesic mild cognitive impairment and mild Alzheimer's disease: A pilot study. *Journal of Alzheimer's Disease* 2011;**25**(4):679-94

Not a disease modification trial

Reference	Reason for exclusion
Butchart J, Brook L, Hopkins V, Teeling J, Puntener U, Culliford D, et al. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. <i>Neurology</i> 2015; 84 (21):2161-8	Not a disease modification trial
Camargo CH, Justus FF, Retzlaff G. The effectiveness of reality orientation in the treatment of Alzheimer's disease American. <i>Journal of Alzheimer's Disease & Other Dementias</i> 2015; 30 (5):527-32	Not a disease modification trial
Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M. Effects of Ginkgo biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: Data from the ICTUS study. <i>Phytomedicine</i> 2014; 21 (6):888-92	Not a disease modification trial
Caramelli P, Laks J, Palmmini ALF, Nitrini R, Chaves MLF, Forlenza OV, et al. Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). <i>Arq Neuropsiquiatr</i> 2014; 72 (6):411-7	Not a disease modification trial
Carlson MC, Tschanz JT, Norton MC, Welsh-Bohmer K, Martin BK, Breitner JC. H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine. <i>Alzheimer disease and associated disorders</i> 2002; 16 (1):24-30	Not a disease modification trial
Ceccato E, Vigato G, Bonetto C, Bevilacqua A, Pizziolo P, Crociani S, et al. STAM protocol in dementia: a multicenter, single-blind, randomized, and controlled trial American. <i>Journal of Alzheimer's Disease & Other Dementias</i> 2012; 27 (5):301-10	Not a disease modification trial
Chan WC, Cheng ST, Shi L, Wang D, Lam LC-W. Would transcranial direct current stimulation (tDCS) enhance the effects of working memory training in older adults with mild neurocognitive disorder due to Alzheimer's disease: study protocol for a randomized controlled trial. <i>Trials</i> 2015; 16 :1-7	Not a disease modification trial
Chapman SB, Weiner MF, Rackley A, Hynan LS, Zientz J. Effects of cognitive-communication stimulation for Alzheimer's disease patients treated with donepezil. <i>Journal of Speech Language & Hearing Research</i> 2004; 47 (5):1149-63	Not a disease modification trial
Chappell AS, Gonzales C, Williams J, Witte MM, Mohs RC, Sperling R. AMPA potentiator treatment of cognitive deficits in Alzheimer disease. <i>Neurology</i> 2007; 68 (13):1008-12	Not a disease modification trial
Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: A multicentre trial. <i>British Medical Journal</i> 1990; 300 (6723):495-9	Not a disease modification trial
Chen J, Huang Y, Wang SX, Li QS, Liang YJ, Guo YN. [18FDG PET cerebral function imaging in 10 vascular dementia patients receiving needling at Baihui(DU20), Shuigou(DU26) and Shenmen(HT7)]. <i>Nan fang yi ke da xue xue bao (Journal of Southern Medical University)</i> 2006; 26 (5):610-2	Full text unavailable in English
Chen TS, Lang HC. Cost-effectiveness analysis of donepezil and rivastigmine for mild to moderate alzheimer's disease in Taiwan. <i>Value in Health</i> 2013; 16 (3):A104	Not published in a peer reviewed journal article or an ongoing trial

Reference	Reason for exclusion
Chen WW, Tian AL, Zhai L, Zhai XL, Zhang YL. [Effect of the xingding allied piracetam injection on improvement of cognitive function in patients with vascular dementia]. <i>Chinese Journal of Clinical Rehabilitation</i> 2005; 9 (16):231-3	Full text unavailable in English
Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. <i>Neurology</i> 2005; 64 (12):2063-8	Not a disease modification trial
Cheung SK. The effects of the music-with-movement intervention of the cognitive functions of people with moderate dementia. <i>Dissertation Abstracts International: Section B: The Sciences and Engineering</i> 2014; 75 (1-B(E))	Not published in a peer reviewed journal article or an ongoing trial
Chiu C-C, Su K-P, Cheng T-C, Liu H-C, Chang C-J, Dewey ME, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study. <i>Progress in Neuro-Psychopharmacology & Biological Psychiatry</i> 2008; 32 (6):1538-44	Not a disease modification trial
Choe YM, Kim KW, Jhoo JH, Ryu SH, Choo IH, Seo EH, et al. Multi-center, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression delaying effect in Alzheimer's disease: Anmri study for atrophy delaying effect. <i>Alzheimer's & dementia</i> 2014; 10 :P302	Not published in a peer reviewed journal article or an ongoing trial
Choi SH, Park KW, Na DL, Han HJ, Kim EJ, Shim YS, et al. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. <i>Current medical research and opinion</i> 2011; 27 (7):1375-83	Not a disease modification trial
Chua KK, Wong A, Kwan P-L, Song JX, Chen LL, Chan A-T, et al. The efficacy and safety of the Chinese herbal medicine Di-Tan decoction for treating Alzheimer's disease: Protocol for a randomized controlled trial. <i>Trials</i> 2015; 16 (1)	Not a disease modification trial
Clare L, Linden DEJ, Woods RT, Whitaker R, Evans SJ, Parkinson CH, et al. Goal-oriented cognitive rehabilitation for people with early-stage alzheimer disease: A single-blind randomized controlled trial of clinical efficacy. <i>American Journal of Geriatric Psychiatry</i> 2010; 18 (10):928-39	Not a disease modification trial
Claus JJ, De Koning I, Van Harskamp F, Breteler MMB, Voet B, Gutzmann H, et al. Lisuride treatment of Alzheimer's disease: A preliminary placebo- controlled clinical trial of safety and therapeutic efficacy. <i>Clinical Neuropharmacology</i> 1998; 21 (3):190-5	Not a disease modification trial
Claxton A, Baker L, Hanson A, Cholerton B, Trittschuh E, Morgan A, et al. Long-acting intranasal insulin detemir improves working memory for adults with mild cognitive impairment or early-stage Alzheimer's dementia. <i>Alzheimer's & dementia</i> 2013; 9 (4 suppl. 1):P657	Not published in a peer reviewed journal article or an ongoing trial
Coelho FG, Andrade LP, Pedroso RV, Santos-Galduroz RF, Gobbi S, Costa JL, et al. Multimodal exercise intervention improves frontal cognitive functions and gait in Alzheimer's disease: a controlled trial. <i>Geriatrics & gerontology international</i> 2013; 13 (1):198-203	Not a disease modification trial

Reference	Reason for exclusion
Coker E. High-dose vitamin B supplements did not slow cognitive decline in patients with mild-to-moderate Alzheimer disease. <i>Evidence Based Nursing</i> 2009; 12 (2):57	Not published in a peer reviewed journal article or an ongoing trial
Comelli M, Lucca U, Spagnoli A. Statistical analysis of the clinical trial of a therapy for Alzheimer's disease. Univariate tests and logistic regression <i>Acta Neurologica</i> 1990; 12 (3):222-30	Not a disease modification trial
Concari L, Gardini S, Dieci F, Copelli S, Ferrari Pellegrini F, Ghetti C, et al. Cognitive and brain metabolism improvement after cognitive stimulation therapy <i>Functional. Neurology</i> 2013; 28 :21-2.	Not published in a peer reviewed journal article or an ongoing trial
Connelly P. High dose vitamin B supplementation does not slow cognitive decline in mild to moderate Alzheimer's disease. <i>Evidence-based mental health</i> 2009; 12 (3):86	Not published in a peer reviewed journal article or an ongoing trial
Connelly PJ, Prentice NP, Cousland G, Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. <i>International journal of geriatric psychiatry</i> 2008; 23 (2):155-60	Not a disease modification trial
Cook C, Fay S, Rockwood K. Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial. <i>International Psychogeriatrics</i> 2008; 20 (5):952-63	Not a disease modification trial
Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. <i>International Journal of Geriatric Psychopharmacology</i> 1998; 1 (2):55-65	Not a disease modification trial
Cornelli U. Treatment of Alzheimer's disease with a cholinesterase inhibitor combined with antioxidants. <i>Neurodegenerative Diseases</i> 2010; 7 (1-3):193-202	Not a disease modification trial
Corona GI SG, Frattini P, Cucchi ML, Zerbi F, Tosca P, Savoldi F. Preliminary data on monoamine metabolic levels in cerebrospinal fluid and in urine during therapy in dementia. <i>IRCS Journal of Medical Science</i> 1983; 11 :923-4	Not a disease modification trial
Corona GL CM, Frattini P, Santagostino G, Schinelli S, Romani A, Pola A, et al. Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia. <i>European Archives of Psychiatry and Neurological Sciences</i> 1989; 239 :79-86	Not a disease modification trial
Corrigan FM VRA, Horrobin DF. Essential fatty acids in Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> 1991; 640 :250-2	Not a disease modification trial
Cotelli M, Calabria M, Manenti R, Rosini S, Zanetti O, Cappa SF, et al. Improved language performance in Alzheimer disease following brain stimulation. <i>Journal of neurology, neurosurgery, and psychiatry</i> 2011; 82 (7):794-7	Not a disease modification trial
Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. <i>Lancet</i> 2004; 363 (9427):2105-15	Not a disease modification trial
Cove J, Jacobi N, Donovan H, Orrell M, Stott J, Spector A. Effectiveness of weekly cognitive stimulation therapy for people with dementia and the	Not a disease modification trial

Reference

Reason for exclusion

additional impact of enhancing cognitive stimulation therapy with a carer training program. *Clinical Interventions In Aging* 2014;**9**:2143-50

Craft S, Claxton A, Baker L, Cholerton B, Hanson A, Callaghan M, et al. Therapeutic effects of long-acting intranasal insulin detemir for Alzheimer's dementia or mild cognitive impairment. *Alzheimer's & dementia* 2013;**9**(4 suppl. 1):139-p40

Not published in a peer reviewed journal article or an ongoing trial

Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in Alzheimer's disease. *Psychopharmacology bulletin* 1991;**28**(1):61-6.

Unable to find a copy of the full text

Crook T, Wilner E, Rothwell A, Winterling D, McEntee W. Noradrenergic intervention in Alzheimer's disease. *Psychopharmacology bulletin* 1991;**28**(1):67-70.

Unable to find a copy of the full text

Crumpacker DW. Retrospective evaluation of constructional praxis measurements among APOE4(-) subjects enrolled in the study of AC-1202 (Axona) in mild to moderate alzheimer's disease (AD). *American Journal of Geriatric Psychiatry* 2012;**1**:S129.

Not published in a peer reviewed journal article or an ongoing trial

Cumbo E. Effects of levetiracetam, phenobarbital and lamotrigine on neuropsychological performance and mood in patients with alzheimer's disease and epilepsy. *Epilepsia* 2009;**50**:101.

Not published in a peer reviewed journal article or an ongoing trial

Cummings J, Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, et al. A randomized, double-blind, placebocontrolled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer's disease. *Alzheimer's & dementia* 2014;**10**:P275

Not a disease modification trial

Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease. *Dementia & Geriatric Cognitive Disorders* 2012;**33**(5):341-53

Not a disease modification trial

Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B. Mefritonate treatment of the cognitive deficits of Alzheimer's disease *Neurology* 1998;**50**(5):1214-21

Not a disease modification trial

Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT. Rivastigmine transdermal patch skin tolerability: Results of a 1-year clinical trial in patients with mild-to-moderate alzheimer's disease. *Clinical Drug Investigation* 2010;**30**(1):41-9

Not a disease modification trial

Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis. *Dementia and geriatric cognitive disorders* 2010;**29**(5):406-12

Not a disease modification trial

Cummings J, Grossberg G, Alva G, Caputo A, Downs P, Strohmaier C. High-dose 13.3 MG/24 h rivastigmine transdermal patch demonstrates efficacy on instrumental activities of daily living: Individual item analysis. *Alzheimer's & dementia* 2012;**8**(4 suppl. 1):P604

Not published in a peer reviewed journal article or an ongoing trial

Cummings J, Hendrix S, Miller M, Pejovic V, Graham S, Tocco M. Extended-release memantine (28 mg, once daily) and sustained behavioral improvement:

Not published in a peer reviewed journal article or an ongoing trial

Reference	Reason for exclusion
Post hoc responder analysis from a randomized trial in patients with moderate to severe alzheimer's disease. <i>Neurology</i> 2012; 78	
Cutler NR, Sramek JJ, Murphy MF, Nash RJ. Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease. <i>Annals of Pharmacotherapy</i> 1992; 26 (9):1118-22	Not a disease modification trial
D'Amico F, Rehill A, Knapp M, Aguirre E, Donovan H, Hoare Z, et al. Maintenance Cognitive Stimulation Therapy: An Economic Evaluation Within a Randomized Controlled Trial. <i>Journal of the American Medical Directors Association</i> 2015; 16 (1):63-70	Not a disease modification trial
Darreh-Shori T, Kadir A, Almkvist O, Grut M, Wall A, Blomquist G, et al. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. <i>Neurobiology of Aging</i> 2008; 29 (2):168-84	Not a disease modification trial
Darreh-Shori T ML, Pettersson T, Hugosson K, Hellstrom-Lindahl E, Andreasen N, Minthon L, et al. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. <i>J Neural Transm</i> 2006; 113 (11):1791-801	Not a disease modification trial
Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. <i>Neuroscience Letters</i> 2001; 300 (3):157-60	Not a disease modification trial
Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. <i>N Engl J Med</i> 1992; 327 (18):1253-9	Not a disease modification trial
Davis RN, Massman PJ, Doody RS Cognitive intervention in Alzheimer disease: a randomized placebo-controlled study. <i>Alzheimer Disease & Associated Disorders</i> 2001; 15 (1):1-9	Not a disease modification trial
de Waal H, Stam CJ, Lansbergen MM, Wieggers RL, Kamphuis PJ, Scheltens P, et al. The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer's disease: a randomised controlled study. <i>PLoS ONE</i>	Not a disease modification trial
Dean R, Siemers E, Carlson C, Estergard W, Sundell K, Henley D, et al. Effects of solanezumab versus placebo administration on biomarkers in people with mild-to-moderate Alzheimer's disease: Results from two phase III clinical trials. <i>Alzheimer's & dementia</i> 2013; 9 (4 suppl. 1):P283	Not published in a peer reviewed journal article or an ongoing trial
Demarin V, Podobnik SS, Storga-Tomic D, Kay G. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study. <i>Drugs under experimental and clinical research</i> 2004; 30 (1):27-33	Not a disease modification trial
Derouesne C, Renault B, Gueguen B, Van Der Linden M, Lacomblez L, Homeyer P, et al. Neuropsychophysiological evaluation of three doses of S 12024-2 in mild-to-moderate Alzheimer's disease. <i>Clinical Drug Investigation</i> 1997; 14 (4):301-6	Not a disease modification trial

Reference	Reason for exclusion
Desire L, Marcade M, Peillon H, Drouin D, Sol O, Pando M. Clinical trials of EHT 0202, a neuroprotective and procognitive alpha-secretase stimulator for Alzheimer's disease. <i>Alzheimers Dement</i> 2009; 1 :255-6	Not published in a peer reviewed journal article or an ongoing trial
Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. <i>The Lancet Neurology</i> 2008; 7 (4):310-8	Not a disease modification trial
Di Lorenzo F. D2 agonist administration restores altered cortical plasticity in Alzheimer's disease patients. <i>Clinical Neurophysiology</i> 2014; 125 :S66.	Not published in a peer reviewed journal article or an ongoing trial
Di Lorenzo F, Martorana A, Bonn S, Caltagirone C, Koch G. D2 agonist administration restores impaired LTP-like cortical plasticity in AD patients. <i>Clinical Neurophysiology</i> 2013; 124 (10):e139-e40.	Not published in a peer reviewed journal article or an ongoing trial
Diehl-Schmid J, Hardlund J, Bentham P, Wischik CM. The first disease-modifying drug trial in frontotemporal dementia: Initial experiences. <i>Alzheimers Dement</i> 2014; 10 :138.	Not published in a peer reviewed journal article or an ongoing trial
Doggrell SA. Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease? <i>Expert Opinion on Pharmacotherapy</i> 2003; 4 (10):1857-60	Not a disease modification trial
Dong GS, Li X, Jiang QH, Yang HQ. [Effects of donepezil treatment on platelets and secretase activities in Alzheimer's disease patients]. <i>Zhonghua yi xue za zhi</i> 2011; 91 (47):3341-5	Full text unavailable in English
D'Onofrio G, Sancarolo D, Addante F, Ciccone F, Cascavilla L, Paris F, et al. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> 2015; 30 (9):965-75	Not a disease modification trial
Doody R, Galvin J, Farlow M, Shah R, Doraiswamy PM, Ferris S, et al. A new 26-week, double-blind, randomized, placebo-controlled, study of AC-1204 (caprylic triglyceride) in mild to moderate Alzheimer's disease: Presentation of study design. <i>Journal of Nutrition, Health and Aging</i> 2012; 16 (9):868	Not published in a peer reviewed journal article or an ongoing trial
Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine. <i>Dementia & Geriatric Cognitive Disorders</i> 2012; 33 (2-3):164-73	Not a disease modification trial
Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3, extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. <i>Archives of Neurology</i> 2001; 58 (3):427-33	Not a disease modification trial
Doody RS GS, Sano M, et al. Dimebon found safe and effective in mild-to-moderate Alzheimer's disease. <i>Brown University Geriatric Psychopharmacology Update</i> 2008; 12 (9):1-6	Not a disease modification trial

Reference	Reason for exclusion
Doran MD. A randomised 26 week double-blind placebo controlled trial to evaluate the safety and efficacy of galantamine in the treatment of dementia secondary to cerebrovascular disease. <i>National Research Register</i> 2003	Not published in a peer reviewed journal article or an ongoing trial
Dorn M. Effect of nimodipine on the well-being, symptoms and efficiency of ambulatory patients with cerebrovascular disorders. 1985	Not published in a peer reviewed journal article or an ongoing trial
Dubois B, McKeith I, Orgogozo J-M, Collins O, Meulien D. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: The MALT Study. <i>International Journal of Geriatric Psychiatry</i> 1999; 14 (11):973-82	Not a disease modification trial
Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. <i>Movement disorders</i> 2012; 27 (10):1230-8	Not a disease modification trial
Dukoff R, Friz J, Lasser, Lev JPK, Sunderland T. A comparison of effects of tacrine with scopolamine versus tacrine with placebo in patients with alzheimer's disease conference abstract. <i>11th Annual Meeting of the American Association for Geriatric Psychiatry San Diego, California, USA 8th-11th March, 1998</i>	Not published in a peer reviewed journal article or an ongoing trial
Dysken M, Kuskowski M, Love S. Ondansetron in the treatment of cognitive decline in Alzheimer dementia. <i>American journal of geriatric psychiatry</i> 2002; 10 (2):212-5	Not a disease modification trial
Dysken MW, Guarino PD, Vertrees JE, Asthana S, Sano M, Llorente M, et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. <i>Alzheimer's & dementia: the journal of the Alzheimer's Association</i> 2014; 10 (1):36-44	Not a disease modification trial
Dysken MW, Mendels J, LeWitt P, Reisberg B, Pomara N, Wood J, et al. Milacemide: A placebo-controlled study in senile dementia of the Alzheimer type. <i>Journal of the American Geriatrics Society</i> 1992; 40 (5):503-6	Not a disease modification trial
Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. <i>JAMA</i> 2014; 311 (1):33-44	Not a disease modification trial
Egger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> 1992; 85 (139):75-80	Not a disease modification trial
Egan M, Yaari R, Liu L, Ryan M, Peng Y, Lines C, et al. Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of Alzheimer's disease. <i>Alzheimers Dement</i> 2011; 1 :S300	Not published in a peer reviewed journal article or an ongoing trial
Eisdorfer C CJ, Wilkie FL. The effect of magnesium pemoline on cognition and behavior. <i>Journals of Gerontology</i> 1968; 23 (3):283-8	Not a disease modification trial
Eliasova I, Anderkova L, Marecek R, Rektorova I. Non-invasive brain stimulation of the right inferior frontal gyrus may improve attention in early Alzheimer's disease: a pilot study. <i>Journal of the Neurological Sciences</i> 2014; 346 (1-2):318-22	Not a disease modification trial

Reference	Reason for exclusion
Emeriau JP, Lehert P, Mosnier M. Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial. <i>Clinical Therapeutics</i> 2000; 22 (7):834-44	Not a disease modification trial
Emre M, Aarsland D, Albanese A, Byrne E, Deuschl G, De Deyn PP, et al. Rivastigmine for Dementia Associated with Parkinson's Disease. <i>N Engl J Med</i> 2004; 351 (24):2509-18	Not a disease modification trial
Emre M, Poewe W, Deyn PP, Barone P, Kulisevsky J, Pourcher E, et al. Long-term safety of rivastigmine in parkinson disease dementia: An open-label, randomized study. <i>Clinical neuropharmacology</i> 2014; 37 (1):9-16	Not a disease modification trial
Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: A randomised, double-blind, placebo-controlled trial. <i>The Lancet Neurology</i> 2010; 9 (10):969-77	Not a disease modification trial
Eriksdotter M, Vedin I, Falahati F, Freund-Levi Y, Hjorth E, Faxen-Irving G, et al. Plasma Fatty Acid Profiles in Relation to Cognition and Gender in Alzheimer's Disease Patients during Oral Omega-3 Fatty Acid Supplementation: The OmegAD Study. <i>Journal of Alzheimer's Disease</i> 2015; 48 (3):805-12	Not a disease modification trial
Erkinjuntti T, Gauthier S, Bullock R, Kurz A, Hammond G, Schwalen S, et al. Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). <i>Journal of Psychopharmacology</i> 2008; 22 (7):761-8	Not a disease modification trial
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. <i>Lancet</i> 2002; 359 (9314):1283-90	Not a disease modification trial
Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV, et al. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. <i>Clinical Therapeutics</i> 2003; 25 (6):1765-82	Not a disease modification trial
Erkinjuntti T, Skoog I, Lane R, Andrews C. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. <i>International journal of clinical practice</i> 2002; 56 (10):791-6	Not a disease modification trial
Etienne P, Dastoor D, Gauthier S, Ludwick R, Collier B. Alzheimer disease: lack of effect of lecithin treatment for 3 months. <i>Neurology</i> 1981; 31 (12):1552-4	Not a disease modification trial
Fabbrini G, Martucci N, Battaglia A, Pamparana F, Annoni K. Nicergoline in the Treatment of Dementia: The Effects on Cerebral Blood Flow Measured by SPECT CONFERENCE ABSTRACT. <i>8th European College of Neuropsychopharmacology Congress Venice, Italy 30th September - 4th October, 1995</i>	Not published in a peer reviewed journal article or an ongoing trial
Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, et al. Evaluation of cycloserine in the treatment of Alzheimer's disease. <i>Journal of geriatric psychiatry and neurology</i> 1995; 8 (4):226-30	Not a disease modification trial

Reference	Reason for exclusion
Falsaperla A, Monici Preti PA, Oliani C. Selegiline versus oxiracetam in patients with Alzheimer-type dementia. <i>Clinical Therapeutics</i> 1990; 12 (5):376-84	Not a disease modification trial
Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. <i>JAMA</i> 1992; 268 (18):2523-9	Not a disease modification trial
Farlow MR. Rivastigmine three times daily improves cognition and response in Alzheimer's disease. <i>Evidence Based Mental Health</i> 2007; 10 (4):116	Not a disease modification trial
Farlow MR, Alva G, Meng X, Olin JT. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. <i>Current medical research and opinion</i> 2010; 26 (2):263-9	Not a disease modification trial
Farlow M, Anand R, Messina Jr J, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. <i>European neurology</i> 2000; 44 (4):236-41	Not a randomised controlled trial/clinical controlled trial
Farlow MR, Doraiswamy M, Meng X, Somogyi M. The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule in Alzheimer's disease. <i>American Journal of Geriatric Psychiatry</i> 2011; 1 :S120	Not a disease modification trial
Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. <i>Clinical Therapeutics</i> 2010; 32 (7):1234-51	Not a disease modification trial
Farokhnia M, Shafiee Sabet M, Iranpour N, Gougol A, Yekehtaz H, Alimardani R, et al. Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer's disease: a double-blind randomized clinical trial. <i>Human Psychopharmacology</i> 2014; 29 (4):351-9	Not a disease modification trial
Feldman H, Coric V, Sperling R, Greenberg S, Bronen R, Sorensen AG, et al. Cerebral microbleeds in a phase 2 clinical trial of mild-to-moderate alzheimer's disease with the gamma secretase inhibitor bms-708163. <i>Alzheimers Dement</i> 2011; 1 :S375.	Not published in a peer reviewed journal article or an ongoing trial
Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, et al. Efficacy of Donepezil on Maintenance of Activities of Daily Living in Patients with Moderate to Severe Alzheimer's Disease and the Effect on Caregiver Burden. <i>Journal of the American Geriatrics Society</i> 2003; 51 (6):737-44	Not a disease modification trial
Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, et al. Economic evaluation of donepezil in moderate to severe Alzheimer disease. <i>Neurology</i> 2004; 63 (4):644-50	Not a disease modification trial
Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. <i>Neurology</i> 2001; 57 (4):613-20	Not a disease modification trial
Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. <i>Neurology</i> 2010; 74 (12):956-64	Not a disease modification trial

Reference	Reason for exclusion
Feldman HH, Lane R, Study G. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> 2007; 78 (10):1056-63	Not a disease modification trial
Feldman HH, Schmitt FA, Olin JT. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. <i>Alzheimer disease and associated disorders</i> 2006; 20 (4):263-8	Not a disease modification trial
Ferris SH, Schmitt FA, Saxton J, Richardson S, MacKell J, Sun Y. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. <i>Alzheimer's research & therapy</i> 2011; 3 (3)	Not a disease modification trial
Finger EC, MacKinley J, Blair M, Oliver LD, Jesso S, Tartaglia MC, et al. Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability. <i>Neurology</i> 2015; 84 (2):174-81	Not a disease modification trial
Fischhof PK, Moslinger-Gehmayr R, Herrmann WM, Friedmann A, Russmann DL. Therapeutic efficacy of vincamine in dementia. <i>Neuropsychobiology</i> 1996; 34 (1):29-35	Not a disease modification trial
Fischhof PK, Saletu B, Ruther E, Litschauer G, Moslinger-Gehmayr R, Herrmann WM. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID). <i>Neuropsychobiology</i> 1992; 26 (1-2):65-70	Not a disease modification trial
Fisman M. Double blind study of lecithin in patients with Alzheimer's disease. <i>The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie</i> 1981; 26 (6):426-8	Not a disease modification trial
Fleisher A, Tariot P, Truran D, Mai J, Aisen P, Cummings J, et al. Brain volume changes with divalproex sodium in alzheimer's disease. <i>Neuropsychopharmacology</i> 2010; 35 :S318-9	Not published in a peer reviewed journal article or an ongoing trial
Flicker C, Ferris SH, Kalkstein D, Serby M. A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease. <i>American Journal of Psychiatry</i> 1994; 151 (1):126-9	Not a disease modification trial
Foerster S, Buschert VC, Buchholz HG, Teipel SJ, Zach C, Hampel H, et al. Positive effects of a 6-month stage-specific cognitive intervention program on brain metabolism in subjects with amnesic mild cognitive impairment (AMCI) and mild Alzheimer's disease (AD). <i>Alzheimers Dement</i> 2009; 1 :205-6.	Not published in a peer reviewed journal article or an ongoing trial
Forbes D. Cognitive stimulation therapy improved cognition and quality of life in dementia. <i>Evidence Based Nursing</i> 2004; 7 (2):54-5	Not a disease modification trial
Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon). <i>European Journal of Neurology</i> 1999; 6 (4):423-9	Not a disease modification trial
Forette F HT, Gracon S, de Rotrou J, Hervy, M P, Lechevalier B, Micas M et al. A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease. <i>European Journal of Neurology</i> 1995; 2 :229-38	Not a disease modification trial

Reference	Reason for exclusion
Forster S, Buschert VC, Buchholz H-G, Teipel SJ, Friese U, Zach C, et al. Effects of a 6-month cognitive intervention program on brain metabolism in amnesic mild cognitive impairment and mild Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> 2011; 25 (4):695-706	Not a disease modification trial
Forster S, Buschert VC, Buchholz HG, Teipel SJ, Rominger A, La Fougere C, et al. Attenuation of cerebral metabolic decline in patients with amnesic mild cognitive impairment (aMCI) or mild Alzheimers disease (AD) joining a six-month stagespecific cognitive intervention program. <i>Nuklear Medizin</i> 2010; 49 (2):A53	Not published in a peer reviewed journal article or an ongoing trial
Förster S, Buschert VC, Teipel SJ, Friese U, Buchholz HG, Drzezga A, et al. Effects of a 6-month cognitive intervention on brain metabolism in patients with amnesic MCI and mild Alzheimer's disease. <i>Journal of Alzheimer's disease</i> 2011; 26 (Suppl 3):337-48	Not a disease modification trial
Foroutanpour K. A phase II, single center, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the safety and efficacy of three different dosages of Cerebrolysin in patients with probable Alzheimer's disease. <i>PRA International report prepared for EBEWE Pharm</i> 2003:1-31.	Not published in a peer reviewed journal article or an ongoing trial
FORUM Pharmaceuticals Inc. <i>NCT02149160 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation.</i> URL: https://clinicaltrials.gov/ct2/show/NCT02149160 . Access date 29 th January 2016	No quantitative outcome relating to disease modification
Francois C, Sintonen H, Sulkava R, Rive B. Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease: a markov model in Finland. <i>Clinical Drug Investigation</i> 2004; 24 (7):373-84	Not a disease modification trial
Freedman M, Rewilak D, Xerri T, Cohen S, Gordon A, Shandling M, et al. L-deprenyl in Alzheimer's disease: Cognitive and behavioral effects <i>Neurology</i> 1998; 50 (3):660-8	Not a disease modification trial
Freund-Levi Y, Vedin I, Hjorth E, Basun H, Faxen Irving G, Schultzberg M, et al. Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: the OmegAD study. <i>Journal of Alzheimer's Disease</i> 2014; 42 (3):823-31	Not a disease modification trial
Frolich L. High-dose rivastigmine patch: Results from the optima study. <i>Neurobiology of aging</i> 2012; 33 :S12	Not published in a peer reviewed journal article or an ongoing trial
Frolich L, Ashwood T, Nilsson J, Eckerwall G. Effects of AZD3480 on cognition in patients with mild-to-moderate alzheimer's disease: A phase IIb dose-finding study. <i>Journal of Alzheimer's disease</i> 2011; 24 (2):363-74	Not a disease modification trial
Gaitán A, Garolera M, Cerulla N, Chico G, Rodriguez-Querol M, Canela-Soler J. Efficacy of an adjunctive computer-based cognitive training program in amnesic mild cognitive impairment and Alzheimer's disease: a single-blind, randomized clinical trial. <i>International Journal of Geriatric Psychiatry</i> 2013; 28 (1):91-9	Not a disease modification trial

Reference	Reason for exclusion
Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. <i>Journal of the American Geriatrics Society</i> 2004; 52 (7):1070-6	Not a disease modification trial
Gang MG. Effect of the horticultural intervention program on cognitive function, emotion, communication and behavior in the elderly with Alzheimer's disease. <i>International Psychogeriatrics</i> 2013; 25 :S140.	Not published in a peer reviewed journal article or an ongoing trial
Gault LM, Meier A, Florian H, Gauthier S, Lin Y, Tang Q, et al. A phase 2 trial of the efficacy and safety of the alpha7agonistabt-126 as an add-on treatment in mild-to-moderate Alzheimer's dementia. <i>Alzheimer's & dementia</i> 2014; 10 :917-8	Not a disease modification trial
Gauthier S. Dimebon improves cognitive function in people with mild to moderate Alzheimer's disease. <i>Evidence Based Mental Health</i> 2009; 12 (1):21- 1	Not published in a peer reviewed journal article or an ongoing trial
Gauthier S, Bouchard R, Lamontagne A, Bailey P, Bergman H, Ratner J, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. <i>N Engl J Med</i> 1990; 322 (18):1272-6	Not a disease modification trial
Gavrilova SI, Kalyn Ia B, Kolykhalov IV, Roshchina IF, Selezneva ND. [Acetyl-L-carnitine (carnitine) in the treatment of early stages of Alzheimer's disease and vascular dementia]. <i>Zhurnal nevrologii i psikiatrii imeni SS Korsakova / Ministerstvo zdavookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikiatrov</i> 2011; 111 (9):16-22	Full text unavailable in English
Gejl M, Egejord L, Moller A, Hansen SB, Vang K, Rodell A, et al. GLP-1 analogue liraglutide prevents decline of brain glucose metabolism in alzheimer's disease: Randomized, placebo-controlled double-blinded clinical trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> 2015; 1 :S132-S3.	Not published in a peer reviewed journal article or an ongoing trial
Gelmont D, Dyck-Jones J. Safety of intravenous immunoglobulin therapy in patients with probable alzheimer's disease: A randomized, placebo-controlled clinical study. <i>Journal of allergy and clinical immunology</i> 2015; 135 (2suppl.1):Ab97	Not published in a peer reviewed journal article or an ongoing trial
Giordano M, Dominguez LJ, Vitrano T, Curatolo M, Ferlisi A, Di Prima A, et al. Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD). <i>Archives of Gerontology and Geriatrics</i> 2010; 51 (3):245-9	Not a disease modification trial
Gleason CE, Fischer BL, Dowling NM, Setchell KDR, Atwood CS, Carlsson CM, et al. Cognitive effects of soy isoflavones in patients with Alzheimer's disease. <i>Journal of Alzheimer's disease</i> 2015; 47 (4):1009-19	Not a disease modification trial
Graham S, Hendrix S, Miller M, Pejovic V, Tocco M. Efficacy of high-dose, extended-release memantine (28 MG, once daily): Post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease. <i>Alzheimers Dement</i> 2011; 1 :S782	Not published in a peer reviewed journal article or an ongoing trial

Reference	Reason for exclusion
Graham S, Tocco M, Hendrix S, Hofbauer RK, Perhach JL. Functional communication in patients with moderate Alzheimer's disease treated with memantine. <i>European Neuropsychopharmacology</i> 2010; 20 :S557-8	Not published in a peer reviewed journal article or an ongoing trial
Graham SM, Hendrix S, Miller ML, Pejovic V, Tocco M. Extended-release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe alzheimer's disease: Post hoc analysis from a randomized trial. <i>American Journal of Geriatric Psychiatry</i> 2013; 1 :S139	Not published in a peer reviewed journal article or an ongoing trial
Graham SM, Tocco M, Hendrix S, Hofbauer RK, Miller ML, Perhach JL. Memantine prevents worsening across multiple domains in a trial of patients with moderate Alzheimer's disease. <i>European Neuropsychopharmacology</i> 2010; 20 :S557	Not published in a peer reviewed journal article or an ongoing trial
Green RC, Goldstein FC, Auchus AP, Presley R, Clark W, Van Tuyl L, et al. Treatment trial of oxiracetam in Alzheimer's disease. <i>Archives of Neurology</i> 1992; 49 (11):1135-6	Not a disease modification trial
Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, et al. Donepezil therapy in clinical practice: a randomized crossover study. <i>Archives of neurology</i> 2000; 57 (1):94-9	Not a disease modification trial
Grossberg G, Alva G, Hendrix S, Hofbauer R, Pejovic V, Graham S. Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe alzheimer's disease: Subset analysis of a randomized clinical trial. <i>Neurology</i> 2015; 84	Not published in a peer reviewed journal article or an ongoing trial
Grossberg G, Alva G, Hendrix S, Hofbauer R, Pejovic V, Graham SM. Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: Subsetanalysis of a randomized clinical trial. <i>Alzheimer's & dementia</i> 2014; 10 :P450	Not published in a peer reviewed journal article or an ongoing trial
Grossberg G, Cummings J, Frolich L, Bellelli G, Molinuevo JL, Krahnke T, et al. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease American. <i>Journal of Alzheimer's Disease & Other Dementias</i> 2013; 28 (6):583-91	Not a disease modification trial
Grossberg G, Meng X, Olin JT. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease American. <i>Journal of Alzheimer's Disease & Other Dementias</i> 2011; 26 (1):65-71	Not a disease modification trial
Grossberg GT, Manes F, Allegri R, Robledo LMG, Gloger S, Xie L, et al. Extended-release memantine (28 mg, once daily) improves verbal fluency and behavior in patients with moderate to severe Alzheimer's disease: Results of a multinational, double-blind, placebo-controlled trial. <i>American Journal of Geriatric Psychiatry</i> 2009; 17 :A78	Not published in a peer reviewed journal article or an ongoing trial
Grossman H, Marzloff G, Luo X, LeRoith D, Sano M, Pasinetti G. NIC5-15 as a treatment for Alzheimer's: Safety, pharmacokinetics and clinical variables. <i>Alzheimer's Dement</i> 2009; 1 :259.	Not published in a peer reviewed journal article or an ongoing trial

Reference	Reason for exclusion
Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, et al. A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H3 Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer's Disease. <i>Current Alzheimer research</i> 2014; 11 (1):47-58	Not a disease modification trial
Growdon JH, Corkin S, Huff FJ, Rosen TJ. Piracetam combined with lecithin in the treatment of Alzheimer's disease. <i>Neurobiology of aging</i> 1986; 7 (4):269-76	Not a disease modification trial
Gu C, Shen T, An H, Yuan C, Zhou J, Ye Q, et al. Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson's disease dementia. <i>Neuroscience Letters</i> 2015; 606 :13-7	Not a disease modification trial
Guekht A, Doppler E, Moessler H, Gusev E. Cerebrolysin improves clinical outcome in moderate to moderately severe vascular dementia: Results from a randomized, double-blind, placebo-controlled, multicenter trial. <i>European Journal of Neurology</i> 2009; 16 (S3):391	Not published in a peer reviewed journal article or an ongoing trial
Guekht AB, Moessler H, Novak PH, Gusev EI. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. <i>Journal of stroke and cerebrovascular diseases</i> 2011; 20 (4):310-8	Not a disease modification trial
Guimon J, Blanco J, Caso C. L-Dopa carbidopa treatment of senile dementia: A control study. <i>The European Journal of Psychiatry</i> 1995; 9 (1):29-36	Not a disease modification trial
Gustafson L. Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease. <i>Acta neurologica Scandinavica Supplementum</i> 1993; 149 (Rand):39-41	Not a disease modification trial
Gustafson L, Risberg J, Johanson M, Fransson M, Maximilian VA. Effects of piracetam on regional cerebral blood flow and mental functions in patients with organic dementia. <i>Psychopharmacology</i> 1978; 56 (2):115-7	Not a disease modification trial
Gustavsson A, Van Der Putt R, Jönsson L, McShane R. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> 2009; 24 (10):1072-8	Not a disease modification trial
Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. <i>Journal of Neural Transmission Supplementum</i> 1998; 54 :301-10	Not a disease modification trial
Haan J, Hörr R. [Delay in progression of dependency and need of care of dementia patients treated with Ginkgo special extract EGb 761]. <i>Wiener medizinische Wochenschrift</i> 2004; 154 (21-22):511-4	Full text unavailable in English
Haase J, Halama P, Horr R. [Efficacy of short-term treatment with intravenously administered Ginkgo biloba special extract EGb 761 in Alzheimer type and vascular dementia]. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> 1996; 29 (4):302-9	Full text unavailable in English
Haase J, Halama P, Hörr R. [Effectiveness of brief infusions with Ginkgo biloba Special Extract EGb 761 in dementia of the vascular and Alzheimer type]. <i>Zeitschrift für Gerontologie und Geriatrie</i> 1996; 29 (4):302-9	Full text unavailable in English

Reference	Reason for exclusion
Hager K, Baseman AS, Han JH, Sano M, Richards HM. In a 2-year placebo-controlled randomized trial galantamine-treated patients had lower mortality rates and slower decline in cognition and activities of daily living. <i>Neuropsychopharmacology</i> 2012; 38 :S328.	Not published in a peer reviewed journal article or an ongoing trial
Hager K, Baseman AS, Nye JS, Brashear H, Han J, Sano M, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> 2014; 10 :391-401	Not a disease modification trial
Hagstadius S, Gustafson L, Risberg J. The effects of bromvincamine and vincamine on regional cerebral blood flow and mental functions in patients with multi-infarct dementia. <i>Psychopharmacology</i> 1984; 83 (4):321-6	Not a disease modification trial
Haig G, Meier A, Pritchett Y, Hall C, Gault L, Lenz R. Evaluation of the efficacy and safety of the H3 antagonist ABT-288 in mild-to-moderate Alzheimer's disease. <i>Alzheimers Dement</i> 2012; 1 :601-2	Not published in a peer reviewed journal article or an ongoing trial
Haig GM, Pritchett Y, Meier A, Othman AA, Hall C, Gault LM, et al. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. <i>Journal of Alzheimer's Disease</i> 2014; 42 (3):959-71	Not a disease modification trial
Hancock G, Charlesworth G. Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer's disease and alleviates caregiver burden. <i>Evidence Based Mental Health</i> 2004; 7 (1):20-1	Not a disease modification trial
Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): A randomised, double-blind, placebo-controlled trial. <i>The Lancet</i> 2012; 379 (9815):528-36	Not a disease modification trial
Hanyu H, Sato T, Kiuchi A, Sakurai H, Iwamoto T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. <i>Journal of the American Geriatrics Society</i> 2009; 57 (1):177-9	Not published in a peer reviewed journal article or an ongoing trial
Hara J, Shankle W. Long-term ivig treatment delays progression of Alzheimer's and Lewy body disease. <i>Alzheimers Dement</i> 2011; 1 :S461	Not published in a peer reviewed journal article or an ongoing trial
Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?. <i>American Journal of Psychiatry</i> 2005; 162 (4):676-82	Not a randomised controlled trial/clinical controlled trial
Hashimoto M, Yamashita K, Kato S, Tamai T, Matsumoto I, Tanabe Y, et al. Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function in elderly people with very mild dementia in Japan. <i>Alzheimers Dement</i> 2011; 1 :610-1	Not published in a peer reviewed journal article or an ongoing trial
Hasselbalch SG, Hoffmann K, Frederiksen KS, Sobol NA, Beyer N, Vogel A, et al. A multicentre randomized clinical trial of physical exercise in Alzheimer's disease (AD): Rationale and design of the ADEX study. <i>European Journal of Neurology</i> 2012; 19 :95	Not published in a peer reviewed journal article or an ongoing trial

Reference	Reason for exclusion
Hauer K, Schwenk M, Zieschang T, Essig M, Becker C, Oster P. Physical training improves motor performance in people with dementia: a randomized controlled trial. <i>Journal of the American Geriatrics Society</i> 2012; 60 (1):8-15	Not a disease modification trial
Heiss WD, Kessler J, Mielke R, Szekely B, Herholz K. Long-term effects of phosphatidylserine, pyritinol, and cognitive training in Alzheimer's disease. A neuropsychological, EEG, and PET investigation. <i>Dementia</i> 1994; 5 (2):88-98	Not a disease modification trial
Henderson ST, Barr LJ, Vogel JL, Garvin F. Evidence of an interaction between APOE and IDE in ketone body therapies in mild to moderate Alzheimer's disease. <i>Journal of the Neurological Sciences</i> 2009; 285 :S277.	Not published in a peer reviewed journal article or an ongoing trial
Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled, multicenter trial. <i>Nutrition & metabolism</i> 2009; 6	Not a disease modification trial
Henderson VW, Ala T, Sainani KL, Bernstein AL, Stephenson BS, Rosen AC, et al. Raloxifene for women with Alzheimer disease: A randomized controlled pilot trial. <i>Neurology</i> 2015; 85 (22):1937-44	Not a disease modification trial
Herrmann WM, Stephan K. Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam. <i>International psychogeriatrics</i> 1992; 4 (1):25-44	Not a disease modification trial
Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S. Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. <i>Journal of Psychiatric Research</i> 2012; 46 (6):716-23	Not a disease modification trial
Heyman A, Schmechel D, Wilkinson W, Rogers H, Krishnan R, Holloway D, et al. Failure of long term high-dose lecithin to retard progression of early-onset Alzheimer's disease. <i>Journal of Neural Transmission Supplementum</i> 1987; 24 :279-86	Not a disease modification trial
Hilt DC, Gawryl M, Koenig G, Dgetluck N, Harrison J, Moebius HJ, et al. Positive effects on cognition and clinical function in mild to moderate Alzheimer's disease patients with a selective alpha-7 nicotinic partial agonists: Interpretation of effects based on a PK/PD model. <i>Journal of Nutrition, Health and Aging</i> 2012; 16 (9):819	Not published in a peer reviewed journal article or an ongoing trial
Ho RT, Cheung JK, Chan WC, Cheung IK, Lam LC. A 3-arm randomized controlled trial on the effects of dance movement intervention and exercises on elderly with early dementia. <i>BMC Geriatrics</i> 2015; 15 :127	Not a disease modification trial
Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. <i>Human psychopharmacology</i> 1994; 9 (3):215-22	Not a disease modification trial
Hoffmann K, Frederiksen KS, Sobol NA, Beyer N, Vogel A, Simonsen AH, et al. Preserving cognition, quality of life, physical health and functional ability in Alzheimer's disease: the effect of physical exercise (ADEX trial): rationale and design. <i>Neuroepidemiology</i> 2013; 41 (3-4):198-207	Not a disease modification trial

Reference	Reason for exclusion
Homma A, Takeda M, Imai Y, Udaka F, Hasegawa K, Kameyama M, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: A 24-week, multicenter, double-blind, placebo-controlled study in Japan. <i>Dementia and geriatric cognitive disorders</i> [Internet]. 2000; 11(6):[299-313 pp.].	Not a disease modification trial
Hooghiemstra A, Eggermont L, Flier W, Marum R, Campen J, Koppe P, et al. Feasibility of an RCT on exercise interventions in early-onset dementia: Let's move on! <i>Alzheimer's & dementia</i> 2013;9(4 suppl. 1):P295	Not published in a peer reviewed journal article or an ongoing trial
Hooghiemstra AM, Eggermont LHP, Scheltens P, van der Flier WM, Bakker J, de Greef MHG, et al. Study protocol: EXERCISE and Cognition In Sedentary adults with Early-ONset dementia (EXERCISE-ON). <i>BMC Neurology</i> 2012;12(75)	Not a disease modification trial
Hoogveldt B, Rive B, Severens J, Maman K, Guilhaume C. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in The Netherlands. <i>Neuropsychiatric Disease and Treatment</i> 2011;7(1):313-7	Not a disease modification trial
Howard R. Donepezil or memantine improved cognitive functioning in moderate-to-severe Alzheimer disease. <i>Annals of Internal Medicine</i> 2012;156(12):JC6-JC10	Not a disease modification trial
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. <i>N Engl J Med</i> 2012;366(10):893-903	Not a disease modification trial
Huang WW, Zhang LH, Zhang H, Kong L. [Effects of hydrochloric donepezil in improving cognition and daily life ability in patients with Alzheimer disease]. <i>Chinese Journal of Clinical Rehabilitation</i> 2004;8(25):5378-9	Full text unavailable in English
Huang Y, Chen J, Htut WM, Lai X, Wik G. Acupuncture increases cerebral glucose metabolism in human vascular dementia. <i>International journal of neuroscience</i> 2007;117(7):1029-37	Not a disease modification trial
Huff FJ. Preliminary evaluation of besipirdine for the treatment of Alzheimer's disease. Besipirdine Study Group. <i>Annals of the New York Academy of Sciences</i> 1996;777:410-4	Not a disease modification trial
Huff FJ, Antuono P, Murphy M, Beyer J, Dobson C. Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> 1991;640:263-7	Not a disease modification trial
Hughes LE, Rittman T, Regenthal R, Robbins TW, Rowe JB. Improving response inhibition systems in frontotemporal dementia with citalopram. <i>Brain: a journal of neurology</i> 2015;138(Pt 7):1961-75	Not a disease modification trial
Hwang HR, Choi SH, Yoon DH, Yoon BN, Suh YJ, Lee D, et al. The effect of cognitive training in patients with mild cognitive impairment and early Alzheimer's disease: a preliminary study. <i>Journal of Clinical Neurology</i> 2012;8(3):190-7	Not a disease modification trial
Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, Tribanek M, Hoerr R, et al. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. <i>International journal of geriatric psychiatry</i> 2011;26(11):1186-94	Not a disease modification trial

Reference	Reason for exclusion
Ihl R, Tribanek M, Bachinskaya N. Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial. <i>Journal of the neurological sciences</i> 2010; 299 (1-2):184-7	Not a disease modification trial
Ihl R, Tribanek M, Bachinskaya N. Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial. <i>Pharmacopsychiatry</i> 2012; 45 (2):41-6	Not a disease modification trial
Ikeda M, Mori E, Kosaka K, Iseki E, Hashimoto M, Matsukawa N, et al. Long-term safety and efficacy of donepezil in patients with dementia with lewy bodies: Results from a 52-week, open-label, multicenter extension study. <i>Dementia and Geriatric Cognitive Disorders</i> 2013; 36 (3-4):229-41	Not a disease modification trial
Imbimbo BP, Lucca U, Lucchelli F, Alberoni M, Thal L. A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> 1998; 12 (4):313-22	Not published in a peer reviewed journal article or an ongoing trial
Imbimbo BP, Lucchelli PE. Chronic low dose eptastigmine in Alzheimer patients: Relationship between acetylcholinesterase inhibition and cognitive effects. <i>Neurobiology of Aging</i> 1994; 15 (Suppl 1 S100)	Not published in a peer reviewed journal article or an ongoing trial
Imbimbo BP, Martelli P, Troetel WM, Lucchelli F, Lucca U, Thal LJ. Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease. <i>Neurology</i> 1999; 52 (4):700-8	Not a disease modification trial
Imbimbo BP, Nicoli M, Martini C, Tomelleri GP, Martelli P, Ferrari GP, et al. Acetylcholinesterase assay may predict cognitive response of Alzheimer patients to eptastigmine treatment. <i>European Journal of Clinical Pharmacology</i> 1998; 54 (9-10):809-10	Not a disease modification trial
Imbimbo BP, Troetel WM, Martelli P, Lucchelli F. A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer's disease. <i>Dementia & Geriatric Cognitive Disorders</i> 2000; 11 (1):17-24	Not a disease modification trial
Imbimbo BP, Verdelli G, Martelli P, Marchesini D. Two-year treatment of Alzheimer's disease with eptastigmine. <i>Dementia and Geriatric Cognitive Disorders</i> 1999; 10 (2):139-46	Not a disease modification trial
Imbriano L, Podda L, Rendace L, Lucchese F, Campanelli A, D'Antonio F, et al. Long-lasting cognitive stimulation temporary improves cognitive impairment in patients with Alzheimer's disease: the results from a 6-months follow-up controlled clinical study. <i>Functional Neurology</i> 2013; 28 :36-7	Not published in a peer reviewed journal article or an ongoing trial
Ishizaki J, Meguro K, Ohe K, Kimura E, Tsuchiya E, Ishii H, et al. Therapeutic psychosocial intervention for elderly subjects with very mild Alzheimer disease in a community: the tajiri project. <i>Alzheimer disease and associated disorders</i> 2002; 16 (4):261-9	Not a disease modification trial
Isik AT, Bozoglu E. Acetylcholinesterase inhibition and insulin resistance in late onset Alzheimer's disease. <i>International Psychogeriatrics</i> 2009; 21 (6):1127-33	Not a disease modification trial

Reference	Reason for exclusion
Ito T, Meguro K, Akanuma K, Ishii H, Mori E. A randomized controlled trial of the group reminiscence approach in patients with vascular dementia. <i>Dementia and geriatric cognitive disorders</i> 2007; 24 (1):48-54	Not a disease modification trial
Jack C, Slomkowski M, Gracon S, Hoover T, Felmlee J, Stewart K, et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. <i>Neurology</i> 2003; 60 (2):253-60	Not a disease modification trial
Jack CRSM, Gracon S, Hoover TM, Felmlee JP, Stewart K, Xu YC, Shiung M, et al. MRI as a surrogate end point for disease progression in a therapeutic trial of milameline for Alzheimer's disease. <i>Proceedings of the 8th International Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden 2002; Abstract No: 1325.</i>	Not published in a peer reviewed journal article or an ongoing trial
Jacoby R. Rofecoxib or naproxen do not slow progression of mild to moderate Alzheimer's disease. <i>Evidence Based Mental Health</i> 2003; 6 (4):110	Not published in a peer reviewed journal article or an ongoing trial
Jann MW, Cyrus PA, Eisner LS, Margolin DI, Griffin T, Gulanski B. Efficacy and safety of a loading-dose regimen versus a no-loading-dose regimen of metrifonate in the symptomatic treatment of Alzheimer's disease: a randomized, double-masked, placebo-controlled trial. Metrifonate Study Group. <i>Clinical Therapeutics</i> 1999; 21 (1):88-102	Not a disease modification trial
Jelcic N, Agostini M, Meneghello F, Busse C, Parise S, Galano A, et al. Feasibility and efficacy of cognitive telerehabilitation in early Alzheimer's disease: a pilot study. <i>Clinical Interventions In Aging</i> 2014; 9 :1605-11	Not a disease modification trial
Jelcic N, Cagnin A, Meneghello F, Turolla A, Ermani M, Dam M. Effects of lexical-semantic treatment on memory in early Alzheimer disease: an observer-blinded randomized controlled trial. <i>Neurorehabilitation & Neural Repair</i> 2012; 26 (8):949-56	Not a disease modification trial
Jeong YH WR, Park CH, Suh YH. Therapeutic potentials of mefenamic acid for the treatment of Alzheimer's disease. <i>Neurobiology of Aging</i> 2004; 25 :s589	Not published in a peer reviewed journal article or an ongoing trial
Jesso S, Diodati D, Morlog D, Pasternak S, Kertesz A, Finger E. A randomized, Double-Blind, Placebo Controlled, cross-Over study of the effects of oxytocin in patients with frontotemporal dementia. <i>Dementia and Geriatric Cognitive Disorders</i> 2010; 30 :98	Not a disease modification trial
Jhee SS, Fabbri L, Piccinno A, Monici P, Moran S, Zarotsky V, et al. First clinical evaluation of ganstigmine in patients with probable Alzheimer's disease. <i>Clinical neuropharmacology</i> 2003; 26 (3):164-9	Not a disease modification trial
Joffres C, Bucks RS, Haworth J, Wilcock GK, Rockwood K. Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis. <i>Dementia & Geriatric Cognitive Disorders</i> 2003; 15 (1):26-33	Not a disease modification trial
Johansson C, Ballard C, Hansson O, Palmqvist S, Minthon L, Aarsland D, et al. Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. <i>International journal of geriatric psychiatry</i> 2011; 26 (2):206-13	Not a randomised controlled trial/clinical controlled trial

Reference	Reason for exclusion
Johannsen P, Salmon E, Hampel H, Xu Y, Richardson S, Qvitzau S, et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease. <i>CNS drugs</i> 2006; 20 (4):311-25	Not a disease modification trial
Johnsen K, Brynne N, Annas P, Hannesdottir K, Alexander R, Segerdahl M. The effects of AZD1446 (A neuronal nicotinic receptor agonist) on quantified electroencephalography (QEEG) in patients with mild-to-moderate Alzheimer's disease. Quantitative measurements using a QEEG cholinergic index. <i>Journal of Nutrition, Health and Aging</i> 2013; 17 (9):834	Not published in a peer reviewed journal article or an ongoing trial
Johnson KH. Donepezil minimally effective for patients with vascular dementia <i>Journal of Family Practice</i> 2004; 53 (3):181-2	Not a disease modification trial
Johnson NA, Rademaker A, Weintraub S, Gitelman D, Wienecke C, Mesulam M. Pilot trial of memantine in primary progressive aphasia. <i>Alzheimer Disease & Associated Disorders</i> 2010; 24 (3):308	Not published in a peer reviewed journal article or an ongoing trial
Jolkkonen JT, Soininen HS, Riekkinen PJ. The effect of an ACTH4-9 analog (Org2766) on some cerebrospinal fluid parameters in patients with Alzheimer's disease. <i>Life Sciences</i> 1985; 37 (7):585-90	Not a disease modification trial
Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. <i>Drugs & Aging</i> 2004; 21 (9):607-20	Not a disease modification trial
Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, et al. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. <i>International journal of geriatric psychiatry</i> 2004; 19 (1):58-67	Not a disease modification trial
Jorgenson S BA, Andersen J, Jensen HV, Olafsson K, Arup P, & Moller SE. Fluvoxamine treatment of dementia: tryptophan levels. <i>Biological Psychiatry</i> 1993; 34 (8):587-8.	Not published in a peer reviewed journal article or an ongoing trial
Jubert J, Navarra J, Canals R, Balaguer M. [Neuropsychologic evaluation of the action of oxovinca in the syndrome of diffuse deterioration of vascular origin]. <i>Medicina Clínica</i> 1980; 75 (3):115-21	Full text unavailable in English
Kadir A, Darreh-Shori T, Almkvist O, Wall A, Grut M, Strandberg B, et al. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. <i>Neurobiology of Aging</i> 2008; 29 (8):1204-17	Not a disease modification trial
Kalman J, Juhasz A, Rimanoczy A, Palotas A, Palotas M, Szabo Z, et al. Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease. <i>Dementia & Geriatric Cognitive Disorders</i> 2003; 16 (1):31-4	Not a disease modification trial
Kamphuis P, Verhey F, Olde Rikkert M, Twisk J, Swinkels S, Scheltens P. Efficacy of a medical food on cognition in Alzheimer's Disease: Results from secondary analyses of a randomized, controlled trial. <i>Journal of Nutrition, Health & Aging</i> 2011; 15 (8):720-4	Not a disease modification trial

Reference	Reason for exclusion
Kanowski S, Hoerr R. Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. <i>Pharmacopsychiatry</i> 2003; 36 (6):297-303	Not a disease modification trial
Karaman Y, Erdogan F, Köseoglu E, Turan T, Ersoy AO. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. <i>Dementia and geriatric cognitive disorders</i> 2005; 19 (1):51-6	Not a disease modification trial
Keller C, Kadir A, Forsberg A, Porras O, Nordberg A. Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. <i>Journal of Alzheimer's disease</i> 2011; 24 (1):109-23	Not a disease modification trial
Kemp PM, Holmes C, Hoffmann S, Wilkinson S, Zivanovic M, Thom J, et al. A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease. <i>Journal of neurology, neurosurgery, and psychiatry</i> 2003; 74 (11):1567-70	Not a disease modification trial
Kennelly S, Abdullah L, Crawford F, Mullan M, Kenny RA, Lawlor B. APOE E4 genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients-an open-label trial. <i>Irish Journal of Medical Science</i> 2011; 180 :S325	Not published in a peer reviewed journal article or an ongoing trial
Kennelly S, Abdullah L, Paris D, Parish J, Mathura V, Mullan M, et al. Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug nilvadipine: Results from a 6-week open label study. <i>International Journal of Geriatric Psychiatry</i> 2011; 26 (10):1038-45	Not a disease modification trial
Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. <i>Dementia & Geriatric Cognitive Disorders</i> 2008; 25 (2):178-85	Not a disease modification trial
Kim SY, Choi SH, Rollema H, Schwam EM, McRae T, Dubrava S, et al. Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's disease. <i>Dementia & Geriatric Cognitive Disorders</i> 2014; 37 (3-4):232-45	Not a disease modification trial
Koch HJ, Szecey A. A randomized controlled trial of prednisone in Alzheimer's disease. <i>Neurology</i> 2000; 55 (7):1067	Not published in a peer reviewed journal article or an ongoing trial
Knapp MJ, Gracon SI, Davis CS, Solomon PR, Pendlebury WW, Knopman DS. Efficacy and safety of high-dose tacrine: A 30-week evaluation. <i>Alzheimer disease and associated disorders</i> 1994; 8 (Suppl. 2):22-31	Not a disease modification trial
Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. <i>Journal of the American Medical Association</i> 1994; 271 (13):985-91	Not a disease modification trial
Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. <i>Neurology</i> 1996; 47 (1):166-77	Not a disease modification trial
Knott V, Engeland C, Mohr E, Mahoney C, Ilivitsky V. Acute nicotine administration in Alzheimer's disease: an exploratory EEG study. <i>Neuropsychobiology</i> 2000; 41 (4):210-20	Not a disease modification trial

Reference	Reason for exclusion
<p>Knott V, Mohr E, Mahoney C, Engeland C, Ilivitsky V. Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease. <i>Neuropsychobiology</i> 2002;45(3):156-60</p>	<p>Not a disease modification trial</p>
<p>Kolykhalov IV, Gavrilova SI, Kalyn Ia B, Selezneva ND, Fedorova Ia B. [Efficacy, safety and tolerability of a single dose of akatinol memantine in comparison to two-doses in patients with moderately expressed and moderately severe dementia in Alzheimer's disease]. <i>Zhurnal nevrologii i psikiatrii imeni SS Korsakova / Ministerstvo zdravookhraneniia i meditsinskoj promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikiatrov</i> 2012;112(1):35-9</p>	<p>Full text unavailable in English</p>
<p>Krishnan K, Charles H, Doraiswamy P, Mintzer J, Weisler R, Yu X, et al. Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer's Disease. <i>The American Journal of Psychiatry</i> 2003;160(11):2003-11</p>	<p>Not a disease modification trial</p>
<p>Kruntoradova K, Mandelikova M, Mlcoch T, Dolezal T. Cost-effectiveness analysis of ginkgo biloba extract (EGB761-tanakan) for the treatment of dementia in The Czech Republic. <i>Value in Health</i> 2015;18(7):A756</p>	<p>Not published in a peer reviewed journal article or an ongoing trial</p>
<p>Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. <i>European Journal of Neurology</i> 2000;7(2):159-69</p>	<p>Not a disease modification trial</p>
<p>Kwak YS, Um SY, Son TG, Kim DJ. Effect of regular exercise on senile dementia patients. <i>Int J Sports Med</i> 2008;29(6):471-4</p>	<p>Not a disease modification trial</p>
<p>Kwok T, Lee J, Law CB, Pan PC, Yung CY, Choi KC, et al. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. <i>Clinical Nutrition</i> 2011;30(3):297-302</p>	<p>Not a disease modification trial</p>
<p>Kwon JC, Kim EG, Kim JW, Kwon Oh D, Yoo BG, Yi HA, et al. A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in binswanger-type subcortical vascular dementia. <i>American Journal of Alzheimer's Disease and other Dementias</i> 2009;24(4):293-301</p>	<p>Not a disease modification trial</p>
<p>Kyowa Hakko Kirin Pharma, Inc. <i>NCT02127476 A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease</i>. URL: https://clinicaltrials.gov/ct2/show/NCT02127476. Accessed 29th January 2016</p>	<p>No quantitative outcome relating to disease modification</p>
<p>Kyowa Hakko Kirin Pharma, Inc. <i>NCT02377713 A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease</i>. URL: https://clinicaltrials.gov/ct2/show/NCT02377713. Accessed 29th January 2016</p>	<p>No quantitative outcome relating to disease modification</p>
<p>Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, et al. HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. <i>Aids</i> 2001;15(6):747-51</p>	<p>Not a disease modification trial</p>
<p>Larsson V, Engedal K, Aarsland D, Wattmo C, Minthon L, Londos E. Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. <i>Dementia & Geriatric Cognitive Disorders</i> 2011;32(4):227-34</p>	<p>Not a disease modification trial</p>

Reference	Reason for exclusion
Laxton AW, Tang-Wai DF, McAndrews MP, Zumsteg D, Wennberg R, Keren R, et al. A phase i trial of deep brain stimulation of memory circuits in Alzheimer's disease. <i>Annals of Neurology</i> 2010; 68 (4):521-34	Not a disease modification trial
Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. <i>JAMA: Journal of the American Medical Association</i> 1997; 278 (16):1327-32	Not a disease modification trial
Leach L. Cognitive stimulation therapy improves cognition and quality of life in older people with dementia. <i>Evidence Based Mental Health</i> 2004; 7 (1):19	Not a disease modification trial
Lee DA, Ngo LY, Adamiak B, Gelmont D. A Confirmatory phase 3 randomized, double-blind, placebo-controlled studyof the safetyand ffectiveness of immune globulin intravenous (human), 10% solution (gammagard liquid/kiovig) for the treatment of mild to moderate Alzheimer's disease. <i>Alzheimers Dement</i> 2011; 1 :S783-4	Not published in a peer reviewed journal article or an ongoing trial
Lee DY, Kim KW, Jhoo JH, Ryu SH, Choo H, Seo EH, et al. A multicenter, randomized, placebocontrolled, double-blind clinicaltrial of escitalopram on its atrophydelaying effect in Alzheimer's disease. <i>Alzheimer's & dementia</i> 2012; 8 (4 suppl. 1):603	Not published in a peer reviewed journal article or an ongoing trial
Lee GY, Yip CC, Yu EC, Man DW. Evaluation of a computer-assisted errorless learning-based memory training program for patients with early Alzheimer's disease in Hong Kong: a pilot study. <i>Clinical interventions in aging</i> 2013; 8 :623-33	Not a disease modification trial
Lefevre G, Sedek G, Jhee SS, Leibowitz MT, Huang HL, Enz A, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. <i>Clinical Pharmacology & Therapeutics</i> 2008; 83 (1):106-14	Not a disease modification trial
Lenz RA, Pritchett YL, Berry SM, Llano DA, Han S, Berry DA, et al. Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease. <i>Alzheimer disease and associated disorders</i> 2015; 29 (3):192-9	Not a disease modification trial
Leroi I, Atkinson R, Overshott R. Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. <i>International journal of geriatric psychiatry</i> 2014; 29 (9):899-905	Not a disease modification trial
Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. <i>International journal of geriatric psychiatry</i> 2004; 19 (1):1-8	Not a disease modification trial
Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. <i>Movement Disorders</i> 2009; 24 (8):1217-21	Not a disease modification trial
Levin OS, Batukaeva LA, Smolentseva IG, Amosova NA. [Efficacy and safety of memantine in dementia with Lewy bodies]. <i>Zhurnal nevrologii i psikiatrii imeni SS Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi</i>	Full text unavailable in English

Reference

Reason for exclusion

promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikiatrov 2008;**108**(5):39-46

Levin OS, Batukaeva LA, Smolentseva IG, Amosova NA. Efficacy and safety of memantine in Lewy body dementia. *Neuroscience & Behavioral Physiology* 2009;**39**(6):597-604

Not a disease modification trial

Levy A, Brandeis R, Treves TA, Meshulam Y, Mawassi F, Feiler D, et al. Transdermal physostigmine in the treatment of Alzheimer's disease. *Alzheimer disease and associated disorders* 1994;**8**(1):15-21

Not a disease modification trial

Li CH, Liu CK, Yang YH, Chou MC, Chen CH, Lai CL. Adjunct effect of music therapy on cognition in Alzheimer's disease in Taiwan: a pilot study. *Neuropsychiatric Disease & Treatment* 2015;**11**:291-6

Not a disease modification trial

Liang E, Wagg J, Kurth M, Abushakra S. Effects of ELND005 (scyllo-inositol) on neuropsychiatric symptoms (NPS) in mild / moderate AD: Correlations of ELND005 exposures to neuropsychiatric outcomes in a 78-week phase 2 study. *Journal of Nutrition, Health and Aging* 2012;**16**(9):839

Not published in a peer reviewed journal article or an ongoing trial

Liang J, Li F, Wei C, Song H, Wu L, Tang Y, et al. Rationale and design of a multicenter, phase 2 clinical trial to investigate the efficacy of traditional Chinese medicine SaiLuoTong in vascular dementia. *Journal of Stroke & Cerebrovascular Diseases* 2014;**23**(10):2626-34

Not a disease modification trial

Liang P, Wang Z, Qian T, Li K. Acupuncture stimulation of Taichong (Liv3) and Hegu (LI4) modulates the default mode network activity in Alzheimer's disease American. *Journal of Alzheimer's Disease & Other Dementias* 2014;**29**(8):739-48

Not a disease modification trial

Likitjaroen Y, Meindl T, Friese U, Wagner M, Buerger K, Hampel H, et al. Longitudinal changes of fractional anisotropy in Alzheimer's disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study. *European Archives of Psychiatry & Clinical Neuroscience* 2012;**262**(4):341-50

Not a disease modification trial

Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, et al. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: A randomized, double-blind, placebo-controlled trial. *Biological psychiatry* 2014;**75**(9):678-85

Not a disease modification trial

Lin CH, Chen PK, Chang YC, Chuo LJ, Chen YS, Tsai GE, et al. Enhancement of NMDA neurotransmission for the treatment of early-phase Alzheimer's disease. *Journal of neurochemistry* 2014;**130**:34

Not published in a peer reviewed journal article or an ongoing trial

Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. *Neurology* 2001;**57**(3):467-73

No participants with mild or moderate dementia

Liu X, Zhang J, Sun D, Fan Y, Zhou H, Fu B. Effects of fluoxetine on brain-derived neurotrophic factor serum concentration and cognition in patients with vascular dementia. *Clinical Interventions In Aging* 2014;**9**:411-8

Not a disease modification trial

Reference	Reason for exclusion
Liu-Seifert H, Andersen S, Holdridge K, Siemers E. Delayed-start analyses of solanezumab phase 3 studies in mild Alzheimer's disease. <i>Neurology</i> 2015; 84	Not published in a peer reviewed journal article or an ongoing trial
Livingston GA, Sax KB, McClenahan Z, Blumenthal E, Foley K, Willison J, et al. Acetyl-L-carnitine in dementia. <i>International Journal of Geriatric Psychiatry</i> 1991; 6 (12):853-60	Not a disease modification trial
Lloret A, Badía MC, Mora NJ, Pallardó FV, Alonso MD, Viña J. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. <i>Journal of Alzheimer's disease</i> 2009; 17 (1):143-9	Not a disease modification trial
Loeb MB, Molloy D, Smieja M, Standish T, Goldsmith CH, Mahony J, et al. A Randomized, Controlled Trial of Doxycycline and Rifampin for Patients with Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> 2004; 52 (3):381-7	Not a disease modification trial
Lojkowska W, Ryglewicz D, Jedrzejczak T, Minc S, Jakubowska T, Jarosz H, et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia <i>Journal of the Neurological Sciences</i> 2003; 216 (1):119-26	Not a disease modification trial
Lopez-Pousa S, Turon-Estrada A, Garre-Olmo J, Pericot-Nierga I, Lozano-Gallego M, Vilalta-Franch M, et al. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. <i>Dementia & Geriatric Cognitive Disorders</i> 2005; 19 (4):189-95	Not a disease modification trial
Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation <i>American Journal of Medical Genetics Part A</i> 2011; 155A (8):1939-48	Not a disease modification trial
Lu PH MD, Mulnard R, et al. Preliminary results suggest testosterone therapy may benefit older patients with AD. <i>Brown University Geriatric Psychopharmacology Update</i> 2006; 10 (2):1-7	Not a disease modification trial
Lucas P, Li D, Lobello K, Liu E, Brashear HR, Styren S. Intravenous bapineuzumab in mild to moderate Alzheimer's disease: Results from two double-blind, placebo-controlled phase 3 trials. <i>Journal of nutrition, health & aging</i> 2013; 17 (9):806-7	Not published in a peer reviewed journal article or an ongoing trial
Lucca U TM, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. <i>Biological Psychiatry</i> 1994; 36 (12):854-6	Not a disease modification trial
Lyketsos CG, Reichman WE, Kershaw P, Zhu Y. Long-term outcomes of galantamine treatment in patients with Alzheimer disease <i>American Journal of Geriatric Psychiatry</i> 2004; 12 (5):473-82	Not a disease modification trial
Magdolna P, Anna J, Agnes F, Gergely D, Csilla FO, Tamas HL, et al. [Acetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer's disease: Friend or foe?]. Acetilkinolin-eszteraz gatlás és szérum lipokinek Alzheimer-korban: Barát vagy ellenség? <i>Neuropsychopharmacologia Hungarica</i> 2012; 14 (1):19-27	Full text unavailable in English

Reference	Reason for exclusion
<p>Maher-Edwards G, Watson C, Ascher J, Barnett C, Boswell D, Davies J, et al. Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> 2015;1(1):23-36</p>	Not a disease modification trial
<p>Maher-Edwards G, Zvartau-Hind M, Hunter A, Gold M, Hopton G, Jacobs G, et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. <i>Current Alzheimer Research</i> 2010;7(5):374-85</p>	Not a disease modification trial
<p>Maina G, Fiori L, Torta R, Fagiani M, Ravizza L, Bonavita E, et al. Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: A double-blind, placebo-controlled study. <i>Neuropsychobiology</i> 1989;21(3):141-5</p>	Not a disease modification trial
<p>Maltby N, Broe GA, Creasey H, Jorm AF, Christensen H, Brooks WS. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial. <i>BMJ</i> 1994;308(6933):879-83</p>	Not a disease modification trial
<p>Marek GJ, Katz DA, Meier A, Greco Nt, Zhang W, Liu W, et al. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease. <i>Alzheimer's & Dementia</i> 2014;10(5 Suppl):S364-73</p>	Not a disease modification trial
<p>Marek G, Katz D, Meier A, Greco N, Zhang W, Liu W, et al. Evaluation of the efficacy and safety of the HSD-1 inhibitor ABT-384 in mild-to-moderate Alzheimer's disease. <i>Alzheimer's & dementia</i> 2012;8(4 suppl. 1):602</p>	Not published in a peer reviewed journal article or an ongoing trial
<p>Marin DB, Bierer LM, Lawlor BA, Ryan TM, Jacobson R, Schmeidler J, et al. L-deprenyl and physostigmine for the treatment of Alzheimer's disease. <i>Psychiatry research</i> 1995;58(3):181-9</p>	Not a disease modification trial
<p>Marsh L, Biglan K, Williams JR. Randomized placebo-controlled trial of memantine for dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> 2009;15:S82</p>	Not published in a peer reviewed journal article or an ongoing trial
<p>Maruyama M, Tomita N, Iwasaki K, Ootsuki M, Matsui T, Nemoto M, et al. Benefits of combining donepezil plus traditional Japanese herbal medicine on cognition and brain perfusion in Alzheimer's disease: a 12-week observer-blind, donepezil monotherapy controlled trial. <i>Journal of the American Geriatrics Society</i> 2006;54(5):869-71</p>	Not published in a peer reviewed journal article or an ongoing trial
<p>Masterman D, Awipi T, Ashford E, Nave S, Yoo K, Vellas B, et al. A nicotinic-alpha-7 partial agonist as adjunctive therapy to stable donepezil. <i>Journal of Nutrition, Health and Aging</i> 2012;16(9):838-9</p>	Not published in a peer reviewed journal article or an ongoing trial
<p>Matsuda O Cognitive stimulation therapy for Alzheimer's disease: the effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patients treated with donepezil. <i>International Psychogeriatrics</i> 2007;19(2):241-52</p>	Not a disease modification trial
<p>Matsuda O, Shido E, Hashikai A, Shibuya H, Kouno M, Hara C, et al. Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer's disease. <i>Psychogeriatrics</i> 2010; 10(4):167-72</p>	Not a disease modification trial
<p>Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. <i>Journal of Psychiatric Research</i> 1997;31(6):645-55</p>	Not a disease modification trial

Reference	Reason for exclusion
<p>McCarney R, Fisher P, Iliffe S, Haselen R, Griffin M, Meulen J, et al. Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial. <i>International journal of geriatric psychiatry</i> 2008;23(12):1222-30</p>	<p>Not a disease modification trial</p>
<p>McCarney R, Warner J, Iliffe S, Haselen R, Griffin M, Fisher P. The Hawthorne Effect: a randomised, controlled trial. <i>BMC medical research methodology</i> 2007;7:30</p>	<p>Not a disease modification trial</p>
<p>McKeith I, Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. <i>Lancet</i> 2000;356(9247):2031-6</p>	<p>Not a disease modification trial</p>
<p>McKeith IG. The clinical trial protocol of the Metrifonate in Alzheimer's Trial (MALT). <i>Dementia & Geriatric Cognitive Disorders</i> 1998;9(Suppl 2):2-7</p>	<p>Not a disease modification trial</p>
<p>McShane RH. Memantine plus donepezil improves physical and mental health in people with Alzheimer's disease. <i>Evidence Based Mental Health</i> 2004;7(3):76</p>	<p>Not a disease modification trial</p>
<p>Mellow AM, Sunderland T, Cohen RM, Lawlor BA, Hill JL, Newhouse PA, et al. Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease. <i>Psychopharmacology</i> 1989;98(3):403-7</p>	<p>Not a disease modification trial</p>
<p>Meyer JS, Chowdhury MH, Xu G, Li YS, Quach M. Donepezil treatment of vascular dementia. <i>Annals of the New York Academy of Sciences</i> 2002;977:482-6</p>	<p>Not a disease modification trial</p>
<p>Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. <i>Journal of the American Geriatrics Society</i> 1989;37(6):549-55</p>	<p>Not a disease modification trial</p>
<p>Minthon L, Edvinsson L, Gustafson L. Tacrine treatment modifies cerebrospinal fluid neuropeptide levels in Alzheimer's disease. <i>Dementia</i> 1994;5(6):295-301</p>	<p>Not a disease modification trial</p>
<p>Minthon L, Gustafson L, Dalzell G, Hagberg B, Nilsson K, Risberg J, et al. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG. <i>Dementia</i> 1993;4(1):32-42</p>	<p>Not a disease modification trial</p>
<p>Mintzer JE, Kershaw P. The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. <i>International journal of geriatric psychiatry</i> 2003;18(4):292-7</p>	<p>Not a disease modification trial</p>
<p>Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy. <i>European journal of neurology</i> 2010;17(3):405-12</p>	<p>Not a disease modification trial</p>
<p>Modrego PJ, Pina MA, Fayed N, Díaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease : a nonrandomised controlled trial with magnetic resonance spectroscopy. <i>CNS Drugs</i> 2006;20(10):867-77</p>	<p>Not a disease modification trial</p>

Reference	Reason for exclusion
Moebius H, Loewen G, Dgetluck N, Hilt D. A randomized, double-blind, placebo-controlled, 24-week, phase 2b outcomes study of 3 different doses of encenicline or placebo in subjects with mild to moderate probable alzheimer's disease. <i>Neurology</i> 2015; 84 .	Not published in a peer reviewed journal article or an ongoing trial
Mohr E, Knott V, Sampson M, Wesnes K, Herting R, Mendis T. Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. <i>Clinical neuropharmacology</i> 1995; 18 (1):28-38	Not a disease modification trial
Mohr E, Nair NP, Sampson M, Murtha S, Belanger G, Pappas B, et al. Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates. <i>Clinical neuropharmacology</i> 1997; 20 (4):338-45	Not a disease modification trial
Mohs RC, Doody R, Morris J, Ieni J, Rogers S, Perdomo C, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients <i>Neurology</i> 2001; 57 (3):481-8	Not a disease modification trial
Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. <i>American Journal of Geriatric Psychiatry</i> 2009; 17 (9):752-9	Not a disease modification trial
Mok V, Wong A, Ho S, Leung T, Lam WWM, Wong KS. Rivastigmine in Chinese patients with subcortical vascular dementia. <i>Neuropsychiatric disease and treatment</i> 2007; 3 (6):943-8	Not a disease modification trial
Molinuevo JL, Berthier ML, Rami L. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: Implications for early diagnosis and treatment. <i>Archives of Gerontology and Geriatrics</i> 2011; 52 (1):18-22	Not a disease modification trial
Moller HJ, Hampel H, Hegerl U, Schmitt W, Walter K. Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type. <i>Pharmacopsychiatry</i> 1999; 32 (3):99-106	Not a disease modification trial
Moller HJ, Maurer I, Saletu B. Placebo-controlled trial of the xanthine derivative propentofylline in dementia. <i>Pharmacopsychiatry</i> 1994; 27 (4):159-65	Not a disease modification trial
Molloy DW, Standish TI, Almeida E, DiLoreto P, Lam-Au C, Guyatt GH. Doxycycline and rifampin for Alzheimer's disease-The DARAD clinical trial. <i>European Geriatric Medicine</i> 2010; 1 :S3	Not published in a peer reviewed journal article or an ongoing trial
Moreno Moreno MDJ. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: A multicenter, double-blind, randomized, placebo-controlled trial. <i>Clinical Therapeutics</i> 2003; 25 (1):178-93	Not a disease modification trial
Moretti DV. Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease. <i>American Journal of Neurodegenerative Diseases</i> 2014; 3 (2):72-83	Not a disease modification trial
Moretti DV, Frisoni GB, Giuliano B, Zanetti O. Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> 2014; 6	Not a disease modification trial

Reference	Reason for exclusion
Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: An open 22-month study. <i>Journal of the neurological sciences</i> 2002; 203-204 :141-6	Not published in a peer reviewed journal article or an ongoing trial
Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients. <i>American journal of Alzheimer's disease and other dementias</i> ; 18 (5):265-72	Not a disease modification trial
Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Ukmar M, et al. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study. <i>International journal of clinical practice</i> 2004; 58 (4):346-53	Not a disease modification trial
Moretti R, Torre P, Antonello RM, Cazzato G, Pizzolato G. Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia <i>American Journal of Alzheimer's Disease & Other Dementias</i> 2008; 23 (2):167-76	Not a disease modification trial
Morgan J, Sethi KD Rivastigmine for dementia associated with Parkinson's disease. <i>Current Neurology & Neuroscience Reports</i> 2005; 5 (4):263-5	Not a disease modification trial
Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. <i>Annals of neurology</i> 2012; 72 (1):41-52	Not a disease modification trial
Mori E, Ikeda M, Nagai R, Matsuo K, Nakagawa M, Kosaka K. Long-term donepezil use for dementia with Lewy bodies: Results from an open-label extension of Phase III trial. <i>Alzheimer's research & therapy</i> 2015; 7 (1)	Not a disease modification trial
Mori S, Mori E, Iseki E, Kosaka K. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. <i>Psychiatry and clinical neurosciences</i> 2006; 60 (2):190-5	Not a disease modification trial
Morillas-Ruiz JM, Rubio-Perez JM, Albaladejo MD, Zafrilla P, Parra S, Vidal-Guevara ML. Effect of an antioxidant drink on homocysteine levels in Alzheimer's patients. <i>Journal of the Neurological Sciences</i> 2010; 299 (1-2):175-8	Not a disease modification trial
Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. <i>Neurology</i> 1998; 50 (5):1222-30	Not a disease modification trial
Moss DE, Berlanga P, Hagan MM, Sandoval H, Ishida C. Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type. <i>Alzheimer Disease & Associated Disorders</i> 1999; 13 (1):20-5	Not a disease modification trial
Mossello E, Tonon E, Caleri V, Tilli S, Cantini C, Cavallini MC, et al. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: A ""real world"" study. <i>Archives of Gerontology and Geriatrics</i> 2004; 38 (SUPPL.):297-307	Not a disease modification trial
Mowla A, Mosavinasab M, Haghshenas H, Haghghi AB. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. <i>Journal of Clinical Psychopharmacology</i> 2007; 27 (5):484-7	Not a disease modification trial

Reference	Reason for exclusion
Mulnard RA, Cotman CW, Kawas C, Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. <i>Journal of the American Medical Association</i> 2000; 283 (8):1007-15	Not a disease modification trial
Muniza R, Serraa CM, Reisberga B, Rojo JM, del Ser T, Casanova JP, et al. Cognitive-motor intervention in Alzheimer's disease: Long-term results from the Maria Wolff trial. <i>Journal of Alzheimer's Disease</i> 2015; 45 (1):295-304	Not a disease modification trial
Muratorio A, Bonuccelli U, Nuti A, Battistini N, Passero S, Caruso V, et al. A neurotropic approach to the treatment of multi-infarct dementia using L-alpha-glycerylphosphorylchlorine. <i>Current therapeutic research, clinical and experimental</i> 1992; 52 (5):741-52	Not a disease modification trial
Na HR, Kim S, Choi SH, Yang DW, Bae HJ, Kim JE, et al. Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report <i>Geriatrics & gerontology international</i> 2011; 11 (1):90-7	Not a disease modification trial
Naber D, Greenspan A, Schreiner A. Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trial. <i>Psychopharmacology</i> 2007; 191 (4):1027-9	No participants with mild or moderate dementia
Nadeau SE, Malloy PF, Andrew ME. A crossover trial of bromocriptine in the treatment of vascular dementia. <i>Annals of Neurology</i> 1988; 24 (2):270-2	Not a disease modification trial
Nakamura Y, Strohmaier C, Tamura K, Kataoka N, Nakano M, Oda S, et al. A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> 2015; 5 (3):361-74	Not a disease modification trial
Nakano S, Asada T, Matsuda H, Uno M, Takasaki M. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. <i>Journal of nuclear medicine</i> 2001; 42 (10):1441-5	Not a disease modification trial
Nakasujja N, Miyahara S, Evans S, Lee A, Musisi S, Katabira E, et al. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. <i>Neurology</i> 2013; 80 (2):196-202	Not a disease modification trial
Nakatsuka M, Nakamura K, Hamanosono R, Takahashi Y, Kasai M, Sato Y, et al. A Cluster Randomized Controlled Trial of Nonpharmacological Interventions for Old-Old Subjects with a Clinical Dementia Rating of 0.5: The Kurihara Project. <i>Dementia and Geriatric Cognitive Disorders Extra</i> 2015; 5 (2):221-32	Not a disease modification trial
Nappi G, Bono G, Merlo P, Borromei A, Caltagirone C, Lomeo C, et al. Long-term nicergoline treatment of mild to moderate senile dementia. Results of a multicentre, double-blind, placebo-controlled study. <i>Clinical drug investigation</i> 1997; 13 (6):308-16	Not a disease modification trial
Napryeyenko O, Borzenko I. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. <i>Arzneimittel-Forschung</i> 2007; 57 (1):4-11	Not a disease modification trial

Reference	Reason for exclusion
Napryeyenko O, Sonnik G, Tartakovsky I. Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial. <i>Journal of the neurological sciences</i> 2009; 283 (1-2):224-9	Not a disease modification trial
Nasab NM, Bahrammi MA, Nikpour MR, Rahim F, Naghibis SN. Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia. <i>JPMA - Journal of the Pakistan Medical Association</i> 2012; 62 (7):677-80	Not a disease modification trial
Nascimento CMC, Teixeira CVL, Gobbi LTB, Gobbi S, Stella F. A controlled clinical trial on the effects of exercise on neuropsychiatric disorders and instrumental activities in women with Alzheimer's disease" Efeitos do exercicio fisico sobre disturbios neuropsiquiatricos e atividades instrumentais da vida diaria em mulheres com doenca de Alzheimer: Um ensaio clinico controlado. <i>Brazilian Journal of Physical Therapy</i> 2012; 16 (3):197-204	Not a disease modification trial
Navia BA, Dafni U, Simpson D, Tucker T, Singer E, McArthur JC, et al. A phase I/II trial of nimodipine for HIV-related neurologic complications. <i>Neurology</i> 1998; 51 (1):221-8	Not a disease modification trial
Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. <i>Neurology</i> 1999; 52 (6):1138-45	Not a disease modification trial
Nicholas T, Knebel W, Gastonguay MR, Bednar MM, Billing CB, Landen JW, et al. Preliminary population pharmacokinetic modeling of pf-04360365, a humanized anti-amyloid monoclonal antibody, in patients with mild-to-moderate Alzheimer's disease. <i>Alzheimers Dement</i> 2009; 1 :253	Not published in a peer reviewed journal article or an ongoing trial
Nordberg A, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Eagle G, et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. <i>Current Alzheimer research</i> 2009; 6 (1):4-14	Not a disease modification trial
Novak G, Brashear HR, Di J, Werth J, Booth K, Margolin R, et al. Efficacy and safety of monthly subcutaneous bapineuzumab. <i>Alzheimer's & dementia</i> 2014; 10 :25	Not published in a peer reviewed journal article or an ongoing trial
Novak PH, Moessler H, Gusev EI, Guekht AB. Cerebrolysin in vascular dementia: A randomized, placebo controlled study. <i>Alzheimers Dement</i> 2009; 1 :249	Not published in a peer reviewed journal article or an ongoing trial
O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. <i>Journal of the American Geriatrics Society</i> 1999; 47 (5):570-8	Not a disease modification trial
O'Caoimh R, Healy L, Gao Y, Svendrovski A, Kerins DM, Eustace J, et al. Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with alzheimer's disease. <i>Journal of Alzheimer's disease</i> 2014; 40 (3):595-603	Not a disease modification trial
Ohnishi T, Sakiyama Y, Okuri Y, Kimura Y, Sugiyama N, Saito T, et al. The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease. <i>Current Alzheimer Research</i> 2014; 11 (2):110-8	Not a disease modification trial
Olazaran J, Muniz R. Cognitive intervention in the initial stages of Alzheimer's disease. <i>Research and practice in Alzheimer's disease</i> 2006; 11 :376-80	Not a disease modification trial

Reference	Reason for exclusion
Olazarán J, Muñoz R, Reisberg B, Peña-Casanova J, Ser T, Cruz-Jentoft AJ, et al. Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. <i>Neurology</i> 2004; 63 (12):2348-53	Not a disease modification trial
Onder G, Zanetti O, Giacobini E, Frisoni GB, Bartorelli L, Carbone G, et al. Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial. <i>British journal of psychiatry</i> 2005; 187 :450-5	Not a disease modification trial
Orgeta V, Leung P, Yates L, Kang S, Hoare Z, Henderson C, et al. Individual cognitive stimulation therapy for dementia: a clinical effectiveness and cost-effectiveness pragmatic, multicentre, randomised controlled trial. <i>Health Technology Assessment (Winchester, England)</i> 2015; 19 (64):1-108	Not a disease modification trial
Orgogozo JM, Rigaud AS, Stöfller A, Möbius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). <i>Stroke; a journal of cerebral circulation</i> 2002; 33 (7):1834-9	Not a disease modification trial
Orrell M, Aguirre E, Spector A, Hoare Z, Woods RT, Streater A, et al. Maintenance cognitive stimulation therapy for dementia: single-blind, multicentre, pragmatic randomised controlled trial. <i>British Journal of Psychiatry</i> 2014; 204 (6):454-61	Not a disease modification trial
Orrell M, Yates LA, Burns A, Russell I, Woods RT, Hoare Z, et al. Individual Cognitive Stimulation Therapy for dementia (iCST): study protocol for a randomized controlled trial. <i>Trials</i> 2012; 13 :172	Not a disease modification trial
Ortega L, Yassuda M, Nunes P, Aprahamian I, Santos F, Santos G, et al. The effects of a multiprofessional cognitive and functional rehabilitation program for patients with mild Alzheimer's disease. <i>Alzheimers Dement</i> 2011; 1 :S660-S1.	Not published in a peer reviewed journal article or an ongoing trial
Othman A, Meier A, William Ritchie C, Florian H, Gault LM, Tang Q. Efficacy and safety of the ALPHA7 agonist ABT-126 as a monotherapy treatment in mild-to-moderate Alzheimer's dementia: Results Of a phase 2b trial. <i>Alzheimer's & dementia</i> 2014; 10 :P137	Not published in a peer reviewed journal article or an ongoing trial
Ott BR, Blake LM, Kagan E, Resnick M. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. <i>Journal of neurology</i> 2007; 254 (3):351-8	Not a disease modification trial
Paasschen J, Clare L, Yuen KS, Woods RT, Evans SJ, Parkinson CH, et al. Cognitive rehabilitation changes memory-related brain activity in people with Alzheimer disease. <i>Neurorehabilitation and neural repair</i> 2013; 27 (5):448-59	Not a disease modification trial
Panisset M, Gauthier S, Moessler H, Windisch M. Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent. <i>Journal of neural transmission</i> 2002; 109 (7-8):1089-104	Not a disease modification trial
Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T. The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. <i>Journal of the neurological sciences</i> 2000; 175 (2):116-23	Not a disease modification trial

Reference	Reason for exclusion
Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. <i>Journal of the neurological sciences</i> 2000; 175 (2):124-34	Not a disease modification trial
Pantoni L, Ser T, Sogliani AG, Amigoni S, Spadari G, Binelli D, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. <i>Stroke; a journal of cerebral circulation</i> 2005; 36 (3):619-24	Not a disease modification trial
Parnetti L, Ambrosoli L, Abate G, Azzini C, Balestreri R, Bartorelli L, et al. Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid. <i>Acta Neurologica Scandinavica</i> 1995; 92 (2):135-40	Not a disease modification trial
Parnetti L, Chiasserini D, Andreasson U, Ohlson M, Huls C, Zetterberg H, et al. Changes in CSF acetyl- and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease <i>Acta Neurologica Scandinavica</i> 2011; 124 (2):122-9	Not a disease modification trial
Paskavitz JF, Gunstad JJ, Samuel JE. Clock drawing and frontal lobe behavioral effects of memantine in Alzheimer's disease: A rater-blinded study. <i>American Journal of Alzheimer's Disease and other Dementias</i> 2006; 21 (6):454-9	Not a disease modification trial
Pasinetti G, Rosenberg P. Repurposing anti-hypertensive drugs for Alzheimer's disease. <i>Alzheimers Dement</i> 2012; 1 :707-P8	Not published in a peer reviewed journal article or an ongoing trial
Pasinetti GM, Rosenberg P. Repurposing cardiovascular drugs as Alzheimer's disease modifying agents. <i>Journal of Nutrition, Health and Aging</i> 2012; 16 (9):822	Not published in a peer reviewed journal article or an ongoing trial
Patel KR. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source. <i>Managed Care</i> 2015; 24 (6):19	Not published in a peer reviewed journal article or an ongoing trial
Peng DT, Xu XH, Wang LN. [Efficiency and safety assessment of donepezil for treating mild and moderate Alzheimer disease]. <i>Chinese Journal of Clinical Rehabilitation</i> 2005; 9 (13):170-2	Full text unavailable in English
Perryman KM, Fitten LJ. Quantitative EEG during a double-blind trial of THA and lecithin in patients with Alzheimer's disease <i>Journal of Geriatric Psychiatry & Neurology</i> 1991; 4 (3):127-33	Not a disease modification trial
Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. <i>American journal of geriatric psychiatry</i> 2006; 14 (8):704-15	Not a disease modification trial
Petit H, Doody RS, Pratt RD. Donepezil improves cognition and global function in Alzheimer's disease: Results from us and multinational phase III clinical trials CONFERENCE ABSTRACT. <i>11th European College of Neuropsychopharmacology Congress Paris, France 31st October - 4th November 1998</i>	Not published in a peer reviewed journal article or an ongoing trial

Reference	Reason for exclusion
Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease. <i>Neurobiology of aging</i> 1995; 16 (1):1-4	Not a disease modification trial
Pfizer. NCT00912288 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled 26-Week Trial To Evaluate The Efficacy And Safety Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease. URL: http://clinicaltrials.gov/show/NCT00912288 . Accessed 29th January 2016	Not published in a peer reviewed journal article or an ongoing trial
Phillips MA, Childs CE, Calder PC, Rogers PJ. No effect of omega-3 fatty acid supplementation on cognition and mood in individuals with cognitive impairment and probable Alzheimer's disease: A randomised controlled trial. <i>International Journal of Molecular Sciences</i> 2015; 16 (10):24600-13	Not a disease modification trial
Pirttilä T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. <i>European journal of neurology</i> 2004; 11 (11):734-41	Not a disease modification trial
Pitkälä KH, Pöysti MM, Laakkonen M-L, Tilvis RS, Savikko N, Kautiainen H, et al. Effects of the Finnish Alzheimer Disease Exercise Trial (FINALEX): A Randomized Controlled Trial. <i>JAMA Internal Medicine</i> 2013; 173 (10):894-901	Not a disease modification trial
Pitkala K, Raivio M, Laakkonen ML, Tilvis R, Kautiainen H, Strandberg T. Effects of intensive exercise intervention on Alzheimer's patients - A randomized, controlled trial. <i>European geriatric medicine</i> 2011; 2 :S59	Not published in a peer reviewed journal article or an ongoing trial
Pitkala KH, Raivio MM, Laakkonen ML, Tilvis RS, Savikko N, Kautiainen H, et al. Effectiveness and costs of intensive exercise intervention on Alzheimer's patients-A randomized, controlled trial. <i>European Geriatric Medicine</i> 2013; 4 :S8	Not published in a peer reviewed journal article or an ongoing trial
Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. <i>Movement Disorders</i> 2006; 21 (4):456-61	Not a disease modification trial
Pomara N, Block R, Abraham J. Combined cholinergic precursor treatment and dihydroergotoxine mesylate in Alzheimer's disease. <i>IRCS Medical Science</i> 1983; 11 (12):1048-9	Not a disease modification trial
Pomara N, Ott BR, Peskind E, Resnick E. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: Secondary analyses from a placebo-controlled randomized trail. <i>Alzheimer Disease and Associated Disorders</i> 2007; 21 (1):60-4	Not a disease modification trial
Poole Hoffmann V, Case M, Hake AM. Effects of treatment with solanezumab in patients with alzheimer's disease who receive current standard of care. <i>Journal of nutrition, health & aging</i> 2013; 17 (9):847-8	Not published in a peer reviewed journal article or an ongoing trial
Poon P, Hui E, Dai D, Kwok T, Woo J. Cognitive intervention for community-dwelling older persons with memory problems: telemedicine versus face-to-face treatment. <i>International Journal of Geriatric Psychiatry</i> 2005; 20 (3):285-6	Not a disease modification trial
Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. <i>Current Alzheimer research</i> 2008; 5 (1):83-9	Not a disease modification trial

Reference	Reason for exclusion
Potkin SG, Alva G, Gunay I, Koumaras B, Chen M, Mirski D. A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia. <i>Drugs and Aging</i> 2006; 23 (3):241-9	Not a disease modification trial
Prasher VP, Huxley A, Haque MS. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease - Pilot study. <i>International Journal of Geriatric Psychiatry</i> 2002; 17 (3):270-8	Not a disease modification trial
Pratt RD. Patient populations in clinical studies of donepezil in vascular dementia. <i>International psychogeriatrics</i> 2003; 15 (Suppl. 1):195-200	Not a disease modification trial
Prentice N, Van Beck M, Dougall NJ, Moffoot APR, O'Carroll RE, Goodwin GM, et al. A double-blind, placebo-controlled study of tacrine in patients with Alzheimer's disease using SPET. <i>Journal of Psychopharmacology</i> 1996; 10 (3):175-81	Not a disease modification trial
Pressman P, Gottfried JA. Journal Club: A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. <i>Neurology</i> 2012; 79 (4):33-6	Not published in a peer reviewed journal article or an ongoing trial
Rabey J, Dobronevsky E, Marton RG, Aichenbau S, Khaigrech M. Improved cognitive function following treatment of Alzheimer's patients with repetitive transcranial magnetic stimulation (rtms) interlaced with cognitive learning treatment. <i>Alzheimers Dement</i> 2011; 1 :S694-S5.	Not published in a peer reviewed journal article or an ongoing trial
Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. <i>Neurology</i> 2011; 76 (16):1389-94	Not a disease modification trial
Rankinen, T. <i>NCT00083811 A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease</i> . URL: http://clinicaltrials.gov/ct2/show/NCT0083811 . Accessed 29th January 2016	Not published in a peer reviewed journal article or an ongoing trial
Randolph C, Roberts JW, Tierney MC, Bravi D, Mouradian MM, Chase TN. D-cycloserine treatment of Alzheimer disease. <i>Alzheimer Disease & Associated Disorders</i> 1994; 8 (3):198-205	Not a disease modification trial
Raskind M, Liang E, Sperling R, Boxer A, Ross J, Brody M, et al. Pharmacokinetics and pharmacodynamics of bapineuzumab following multiple intravenous infusions in patients with mild-to-moderate Alzheimer's disease. <i>Alzheimers Dement</i> 2009; 1 :415-6	Not published in a peer reviewed journal article or an ongoing trial
Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. <i>Archives of Neurology</i> 2004; 61 (2):252-6	Not a disease modification trial
Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. <i>Neurology</i> 2000; 54 (12):2261-8	Not a disease modification trial
Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo	Not a disease modification trial

Reference	Reason for exclusion
controlled, crossover study. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> 2005; 76 (7):934-9	
Rebok GW, Ball K, Guey LT, Jones RN, Kim H-Y, King JW, et al. Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults. <i>Journal of the American Geriatrics Society</i> 2014; 62 (1):16-24	Not a disease modification trial
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. <i>Archives of Neurology</i> 2006; 63 (1):49-54	Not a disease modification trial
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. <i>N Engl J Med</i> 2003; 348 (14):1333-41	Not a disease modification trial
Reisberg B, Kenowsky S, Boksay I, Golomb J, Heller S, Ghimire S, et al. Memantine and comprehensive, individualized, person-centered management (CI-PCM) of Alzheimer's disease: A randomized controlled trial. <i>Alzheimers Dement</i> 2013; 1 :295-6	Not published in a peer reviewed journal article or an ongoing trial
Riekkinen M, Laakso MP, Jakala P, Riekkinen Jr P. Clonidine impairs sustained attention and memory in Alzheimer's disease. <i>Neuroscience</i> 1999; 92 (3):975-82	Not a disease modification trial
Riekkinen P, Kuikka J, Soininen H, Helkala EL, Hallikainen M, Riekkinen P. Tetrahydroaminoacridine modulates technetium-99m labelled ethylene dicycysteinate retention in Alzheimer's disease measured with single photon emission computed tomography imaging. <i>Neuroscience letters</i> 1995; 195 (1):53-6	Not a disease modification trial
Riekkinen P, Riekkinen M. THA improves word priming and clonidine enhances fluency and working memory in Alzheimer's disease. <i>Neuropsychopharmacology</i> 1999; 20 (4):357-64	Not a disease modification trial
Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. <i>Journal of Alzheimer's Disease</i> 2006; 10 (4):399-406	No participants with mild or moderate dementia
Rigaud AS, André G, Vellas B, Touchon J, Pere JJ, Loria-Kanza Y. [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease]. The results of a 28-weeks controlled study. <i>Presse médicale</i> 2003; 32 (35):1649-54	Full text unavailable in English
Rijpma A, Meulenbroek O, Van Hees AM, Sijben JW, Scheltens P, Olde Rikkert MG. Effects of a medical food on plasma micronutrient and fatty acid levels in mild to moderate Alzheimer's disease. <i>Clinical Nutrition</i> 2014; 33 :S193	Not published in a peer reviewed journal article or an ongoing trial
Rijpma A, Meulenbroek O, van Hees AM, Sijben JW, Vellas B, Shah RC, et al. Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease. <i>Alzheimer's Research & Therapy</i> 2015; 7 (1):51	Not a disease modification trial

Reference	Reason for exclusion
Risner ME, Saunders AM, Altman JFB, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. <i>Pharmacogenomics Journal</i> 2006; 6 (4):246-54	Not a disease modification trial
Rive B, Vercelletto M, Damier FD, Cochran J, Francois C. Memantine enhances autonomy in moderate to severe Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> 2004; 19 (5):458-64	Not a disease modification trial
Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. <i>International Journal of Geriatric Psychiatry</i> 2008; 23 (2):207-14	Not a disease modification trial
Rockwood K, Fay S, Gorman M. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. <i>International journal of geriatric psychiatry</i> 2010; 25 (2):191-201	Not a disease modification trial
Rockwood K, Fay S, Song X, MacKnight C, Gorman M. Video-Imaging Synthesis of Treating Alzheimer's Disease I Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. <i>CMAJ Canadian Medical Association Journal</i> 2006; 174 (8):1099-105	Not a disease modification trial
Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> 2001; 71 (5):589-95	Not a disease modification trial
Rodriguez-Sanchez E, Criado-Gutierrez JM, Mora-Simon S, Muriel-Diaz MP, Gomez-Marcos MA, Recio-Rodriguez JI, et al. Physical activity program for patients with dementia and their relative caregivers: randomized clinical trial in Primary Health Care (AFISDEMyF study). <i>BMC Neurology</i> 2014; 14 :63	Not a disease modification trial
Rogers J, Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., et al. Clinical trial of indomethacin in Alzheimer's disease. <i>Neurology</i> 1993; 43 (8):1609	Not a disease modification trial
Rogers S, Perdomo C, Friedhoff L. Clinical Benefits are Maintained During Long-term Treatment of Alzheimer's Disease with the Acetylcholinesterase Inhibitor, E2020 CONFERENCE ABSTRACT. <i>8th European College of Neuropsychopharmacology Congress Venice, Italy 30th September - 4th October, 1995</i>	Not published in a peer reviewed journal article or an ongoing trial
Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. <i>Archives of Internal Medicine</i> 1998; 158 (9):1021-31	Not a disease modification trial
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. <i>Neurology</i> 1998; 50 (1):136-45	Not a disease modification trial
Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Ieni J, et al. Donepezil improved cognitive and global function in mild-to-moderate Alzheimer disease <i>Evidence-Based Medicine</i> 1998; 3 (5):155	Not a disease modification trial
Rogers SL, Friedhoff LT. Donepezil improves cognition in patients with mild to moderate AD: Results of ADAS-COG analysis in a 30-week phase III study. <i>10th</i>	Not published in a peer reviewed journal article or an ongoing trial

Reference

Reason for exclusion

European College of Neuropsychopharmacology Congress Vienna, Austria 13th-17th September 1997

Rogers SL, Mohs RC, Friedhoff LT. Donepezil (E2020) Improves Cognition and Function in Patients with Mild to Moderately Severe Alzheimer's Disease Results from Phase CONFERENCE ABSTRACT. *150th Annual Meeting of the American Psychiatric Association San Diego, California, USA 17-22 May, 1997*

Not published in a peer reviewed journal article or an ongoing trial

Román GC, Salloway S, Black SE, Royall DR, Decarli C, Weiner MW, et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. *Stroke* 2010;**41**(6):1213-21

Not a disease modification trial

Román GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials. *Dementia & Geriatric Cognitive Disorders* 2005;**20**(6):338-44

Not a disease modification trial

Rosenbloom MH, Barclay TR, Pyle M, Owens BL, Cagan AB, Anderson CP, et al. A single-dose pilot trial of intranasal rapid-acting insulin in apolipoprotein E4 carriers with mild-moderate Alzheimer's disease. *CNS Drugs* 2014;**28**(12):1185-9

Not a disease modification trial

Rosengarten B, Paulsen S, Molnar S, Kaschel R, Gallhofer B, Kaps M. Acetylcholine esterase inhibitor donepezil improves dynamic cerebrovascular regulation in Alzheimer patients. *Journal of Neurology* 2006;**253**(1):58-64

Not a disease modification trial

Roshchina IF, Kolykhalov IV, Selezneva ND, Zharikov GA, Gerasimov NP, GavriloVA SI. [The influence of cerebrolysin on the efficiency of subsequent therapy with amiridine++ in Alzheimer's disease patients (neuropsychological investigation)]. *Zhurnal nevrologii i psikiatrii imeni SS Korsakova / Ministerstvo zdravookhraneniia i meditsinskoj promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikiatrov* 1999;**99**(12):43-6

Full text unavailable in English

Rosler M, Anand R, Cincin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. *BMJ: British Medical Journal* 1999;**318**(7184):633-40

Not a disease modification trial

Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. *BMC Geriatrics* 2013;**13**:56

Not a disease modification trial

Sacktor N, Kieburtz K, Schifitto G, McDermott M, Bourgeois K, Palumbo D, et al. A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment. *Neurology* 1998 Mar 1;**50**(3):645-51.

No participants with mild or moderate dementia

Sadowsky CH, Grossberg GT, Somogyi M, Meng X. Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: A retrospective analysis. *Primary Care Companion to the Journal of Clinical Psychiatry* 2011;**13**(3)

Not a disease modification trial

Reference	Reason for exclusion
Sahakian BJ, Coull JT. Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and mnemonic function using CANTAB. <i>Acta Neurologica Scandinavica Supplementum</i> 1993; 149 :29-35	Not a disease modification trial
Sahakian BJ, Coull JT. Nicotine and tetrahydroaminoacridine: Evidence for improved attention in patients with dementia of the Alzheimer type. <i>Drug development research</i> 1994; 31 (1):80-8	Not a disease modification trial
Sainati SM ID, Talwalker S, Geis GS. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. <i>Proceedings of the 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy; Apr 5-8, Stockholm, Sweden 2000</i> : 180	Not published in a peer reviewed journal article or an ongoing trial
Saletu B, Anderer P, Fischhof PK, Lorenz H, Barousch R, Böhmer F. EEG mapping and psychopharmacological studies with denbufylline in SDAT and MID. <i>Biological psychiatry</i> 1992; 32 (8):668-81	Not a disease modification trial
Saletu B, Hochmayer I, Grunberger J, Bohmer F, Paroubek J, Wicke L, et al. [Therapy of multi-infarct-dementia with nicergoline: Double-blind, clinical, psychometric and EEG-imaging-investigation with two different drug administration schedules]. zur therapie der multiinfarktdemenz mit nicergolin: doppelblinde, klinische, psychometrische und eeg-imaginguntersuchungen mit 2 dosierungsschemata. <i>Wien Med Wochenschr</i> 1987; 137 (22):513-24	Full text unavailable in English
Salloway S, Sperline R, Gregg K, Black R, Grundman M. Cognitive and functional outcomes from a phase II trial of bapineuzumab in mid to moderate Alzheimer's disease. <i>Neurology</i> 2009; 72 (11 Suppl 3):A271, Abstract no: S32.002	Not published in a peer reviewed journal article or an ongoing trial
Salloway S, Sperling R, Gregg K, Yu P, Joshi A, Lu M, et al. Incidence and clinical progression of placebo-treated amyloidnegative subjects with mildto-moderate Alzheimer's disease (AD): Results from the phase III PET substudies of bapineuzumab and solanezumab. <i>Alzheimer's & dementia</i> 2013; 9 (4 suppl. 1):888-9	Not published in a peer reviewed journal article or an ongoing trial
Salloway S, Sperling R, Honig L, Porsteinsson A, Sabbagh M, Liu E, et al. A randomized, double-blind, placebocontrolled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E 4 non-carriers. <i>European journal of neurology</i> 2012; 19 :70	Not published in a peer reviewed journal article or an ongoing trial
Salotti P, De Sanctis B, Clementi A, Fernandez Ferreira M, De Silvestris T. Evaluation of the efficacy of a cognitive rehabilitation treatment on a group of Alzheimer's patients with moderate cognitive impairment: a pilot study. <i>Aging-Clinical & Experimental Research</i> 2013; 25 (4):403-9	Not a disease modification trial
Salva A, Andrieu S, Fernandez E, Schiffrin E, Moulin J, Decarli B, et al. Health and nutrition promotion program for patients with dementia (NutriAlz): Cluster randomized trial. <i>Journal of Nutrition, Health & Aging</i> 2011; 15 (10):822-30	Not a disease modification trial
Salva A, Andrieu S, Fernandez E, Schiffrin EJ, Moulin J, Decarli B, et al. Health and nutritional promotion program for patients with dementia (NutriAlz Study): design and baseline data. <i>Journal of nutrition, health & aging</i> 2009; 13 (6):529-37	Not a disease modification trial

Reference	Reason for exclusion
Samorajski T, Vroulis, G. A., & Smith, R. C. Piracetam plus lecithin trials in senile dementia of the Alzheimer type. <i>Annals of the New York Academy of Sciences</i> 1985	Not a disease modification trial
Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. <i>N Engl J Med</i> 1997; 336 (17):1216-22	Not a disease modification trial
Sanofi, ICD CSD. <i>NCT00104013 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of SR57746A in Patients with Mild-to-Moderate Dementia of the Alzheimer</i> . URL: https://clinicaltrials.gov/ct2/show/NCT00104013 . Accessed January 2016	Not published in a peer reviewed journal article or an ongoing trial
Sanofi, ICD CSD. <i>NCT00103649 18-month Study of the Efficacy of Xaliproden (SR57746A) in Patients with Mild-to-Moderate Dementia of the Alzheimer</i> . URL: https://clinicaltrials.gov/ct2/show/NCT00103649 . Accessed January 2016	Not published in a peer reviewed journal article or an ongoing trial
Santens P, Ventura M. Donepezil in the treatment of mild to moderate Alzheimer's disease: Report of a Belgian multicenter study <i>Acta Neurologica Belgica</i> 2003; 103 (3):159-63	Not a disease modification trial
Saxton J, Hofbauer RK, Woodward M, Gilchrist NL, Potocnik F, Hsu HA, et al. Memantine and functional communication in Alzheimer's disease: results of a 12-week, international, randomized clinical trial. <i>Journal of Alzheimer's disease</i> 2012; 28 (1):109-18	Not a disease modification trial
Schecker M, Pirnay-Dummer P, Schmidtke K, Hentrich-Hesse T, Borchardt D. Cognitive interventions in mild Alzheimer's disease: a therapy-evaluation study on the interaction of medication and cognitive treatment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> 2013; 3 (1):301-11	Not a disease modification trial
Scheltens NME, Van Berckel BNM, Boellaard R, Barkhof F, Van Der Flier WM, Kamphuis PJG, et al. A Dutch 24-week randomised controlled study exploring the Effect of a Nutritional Intervention on brain Glucose Metabolism in early Alzheimer's disease (NL-ENIGMA); Rationale and design. <i>European Geriatric Medicine</i> 2014; 5 :91	Not published in a peer reviewed journal article or an ongoing trial
Scheltens P, Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Wurtman RJ, Wilkinson D, et al. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. <i>Alzheimers Dement</i> 2010; 6 (1):1-10.e1	Not a disease modification trial
Scheltens P, Sperling R, Salloway S, Fox N. Bapineuzumab IV phase 3 results. <i>Journal of Nutrition, Health and Aging</i> 2012; 16 (9):797	Not published in a peer reviewed journal article or an ongoing trial
Scheltens P, Stam C, Shah R, Bennett D, Wieggers R, Hartmann T, et al. Medical nutrition in disease management of Alzheimer's patients. <i>Clinical nutrition</i> 2013; 32 :35	Not published in a peer reviewed journal article or an ongoing trial
Scheltens P, Verhey FRJ, Rikkert MGMO, Kamphuis PJGH, Wilkinson D, Kurz A. The efficacy of a medical food (Souvenaid) in Alzheimer's disease: Results from the first trial and design of future trials. <i>Alzheimers Dement</i> 2009; 1 :258-9	Not published in a peer reviewed journal article or an ongoing trial

Reference	Reason for exclusion
Scherder E, Knol D, van Tol MJ, van Someren E, Deijen JB, Swaab D, et al. Effects of high-frequency cranial electrostimulation on the rest-activity rhythm and salivary cortisol in Alzheimer's disease: a pilot study. <i>Dementia & Geriatric Cognitive Disorders</i> 2006; 22 (4):267-72	Not a disease modification trial
Scherder EJ, Tol MJ, Swaab DF. High-frequency cranial electrostimulation (CES) in patients with probable Alzheimer's disease. <i>American journal of physical medicine & rehabilitation</i> 2006; 85 (7):614-8	Not a disease modification trial
Schiffczyk C, Romero B, Jonas C, Muller F, Riepe MW. Efficacy of multimodal intervention for people with Alzheimer's disease. <i>Alzheimers Dement</i> 2013; 1 :654	Not published in a peer reviewed journal article or an ongoing trial
Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, et al. Memantine and HIV-associated cognitive impairment: A neuropsychological and proton magnetic resonance spectroscopy study. <i>Aids</i> 2007; 21 (14):1877-86	Not a disease modification trial
Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. <i>Neurology</i> 2007; 69 (13):1314-21	Not a disease modification trial
Schmidt R, Ropele S, Pendl B, Ofner P, Enzinger C, Schmidt H, et al. Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> 2008; 79 (12):1312-7	Not a disease modification trial
Schmitt F, Farlow M, Olin J. Effects of rivastigmine on executive function in parkinson's disease dementia: Results: from a 24-week placebo-controlled clinical trial. <i>Annals of Neurology</i> 2009; 66 :48	Not published in a peer reviewed journal article or an ongoing trial
Schmitt FA, Aarsland D, Bronnick KS, Meng X, Tekin S, Olin JT. Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items. <i>American Journal of Alzheimer's Disease & Other Dementias</i> 2010; 25 (5):407-13	Not a disease modification trial
Schmitt FA, Aarsland D, Bronnick KS, Olin JT, Meng X. Evaluating cognitive effects of oral rivastigmine using subscales and items of the ADAS-cog in patients with mild to moderate Parkinson's disease dementia. <i>American Journal of Geriatric Psychiatry</i> 2010; 1 :79	Not published in a peer reviewed journal article or an ongoing trial
Schmitt FA, Farlow MR, Meng X, Tekin S, Olin JT. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia. <i>CNS Neuroscience & Therapeutics</i> 2010; 16 (6):330-6	Not a disease modification trial
Schmitt FA, Saxton J, Ferris SH, Mackell J, Sun Y. Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study. <i>International journal of clinical practice</i> 2013; 67 (10):1050-6	Not a disease modification trial
Schneider L, Porsteinsson A, Farlow M, Shimakura A, Nakagawa M, Iwakami N. The neuroprotective and neurotrophic agent T-817MA for Alzheimer's disease: Randomized, double-blind, placebo controlled proof-of-concept trial outcomes. <i>Alzheimers Dement</i> 2013; 1 :530-1.	Not published in a peer reviewed journal article or an ongoing trial

Reference	Reason for exclusion
Schneider LS, DeKosky ST, Farlow MR, Tariot PN, Hoerr R, Kieser M. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type. <i>Current Alzheimer research</i> 2005; 2 (5):541-51	Not a disease modification trial
Schneider LS, Farlow M. Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> 1997; 826 :317-22	Not a disease modification trial
Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. <i>Neurology</i> 1996; 46 (6):1580-4	Not a disease modification trial
Schneider LS, Farlow MR, Pogoda JM. Potential role for estrogen replacement in the treatment of Alzheimer's dementia. <i>American journal of medicine</i> 1997; 103 (3a):46-50	Not a disease modification trial
Schwam E, Evans R, Nicholas T, Chew R, Davidson W, Ambrose D, et al. PF-04447943: A phase II controlled clinical trial of a selective pde9a inhibitor in Alzheimer's disease. <i>Alzheimers Dement</i> 2011; 1 :695	Not published in a peer reviewed journal article or an ongoing trial
Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. <i>Archives of neurology</i> 2004; 61 (12):1852-6	Not a disease modification trial
Seltzer B, Zolnouni P, Nunez M, Goldman R, Noble Y, Kumar D, et al. Donepezil treatment improves cognitive performance in patients with very mild Alzheimer's disease. <i>European Neuropsychopharmacology; 15th International Congress of the European College of Neuropsychopharmacology, October 5-9, Barcelona, Spain</i> 2002; 12 (Suppl 3):S385	Not published in a peer reviewed journal article or an ongoing trial
Ser T, Lovestone S, Boada-Rovira M, Dubois B, Hull M, Rinne J, et al. A phase II randomized, double-blind, parallel group, 26-week study of GSK-3 inhibitor tideglusib in Alzheimer's disease (argo trial). <i>Alzheimers Dement</i> 2013; 1 :689-90	Not published in a peer reviewed journal article or an ongoing trial
Ser TD, Lovestone S, Rovira MB, Dubois B, Hull M, Rinne J, et al. Argo trial. <i>Alzheimers Dement</i> 2012; 1 :455-6	Not published in a peer reviewed journal article or an ongoing trial
Shah RC, Matthews DC, Andrews RD, Capuano AW, Fleischman DA, VanderLugt JT, et al. An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. <i>Current Alzheimer Research</i> 2014; 11 (6):564-73	Not a disease modification trial
Shankle WR, Hara J. Longitudinal measure of IVIG treatment effect in patients with Alzheimer's and lewy body disease. <i>Alzheimers Dement</i> 2009; 1 :430	Not published in a peer reviewed journal article or an ongoing trial
Shatenstein B, Kergoat M, Reid I, Chicoine ME. Dietary intervention in older adults with early-stage Alzheimer dementia: early lessons learned. <i>Journal of Nutrition, Health & Aging</i> 2008; 12 (7):461-9	Not a disease modification trial
Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, et al. DOMINO-AD protocol: Donepezil and memantine in moderate to severe Alzheimer's disease - A multicentre RCT. <i>Trials</i> 2009; 10 (57)	Not a disease modification trial

Reference	Reason for exclusion
Shifu X, Heqin Y, Peifen Y, Luning W, Jianjun J, Xin M, et al. Efficacy of FPF 1070 (cerebrolysin) in patients with Alzheimer's disease. A multicentre, randomised, double-blind, placebo-controlled trial. <i>Clinical drug investigation</i> 2000; 19 (1):43-53	Not a disease modification trial
Shikiar R, Shakespeare A, Sagnier PP, Wilkinson D, McKeith I, Dartigues JF, et al. The impact of metrifonate therapy on caregivers of patients with Alzheimer's disease: results from the MALT clinical trial. <i>Metrifonate in Alzheimer's Disease Trial. Journal of the American Geriatrics Society</i> 2000; 48 (3):268-74	Not a disease modification trial
Shimizu S, Kanetaka H, Hirose D, Sakurai H, Hanyu H. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: A 12-month, randomized, and open-label trial. <i>Dementia and Geriatric Cognitive Disorders Extra</i> 2015; 5 (1):135-46	Not a disease modification trial
Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> 2014; 38 (1):111-20	Not a disease modification trial
Shrotriya RC, Cutler NR, Sramek JJ, Veroff AE, Hironaka DY. Efficacy and safety of BMY 21,502 in Alzheimer disease. <i>Annals of Pharmacotherapy</i> 1996; 30 (12):1376-80	Not a disease modification trial
Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, Richman DD, et al. Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial. <i>Annals of Neurology</i> 1993; 33 (4):343-9	Not a disease modification trial
Siemers E, Henley D, Sundell K, Sethuraman G, Dean R, Wroblewski K, et al. Evaluating semagacestat, a gammasecretase inhibitor, in a phase iii trial. <i>Alzheimers Dement</i> 2011; 1 :484-5	Not published in a peer reviewed journal article or an ongoing trial
Silva HA, Pathmeswaran A, Gunatilake SB. Efficacy of rivastigmine on activities of daily living in Sri Lankan patients with Alzheimer disease and on improving caregiver burden: a prospective study. <i>Ceylon medical journal</i> 2005; 50 (3):106-9	Not a disease modification trial
Sinforiani E, Iannuccelli M, Mauri M, Costa A, Merlo P, Bono G, Nappi G. Neuropsychological changes in demented patients treated with acetyl-L-carnitine. <i>International journal of clinical pharmacology research</i> 1989; 10 (1-2):69-74	Unable to find a copy of the full text
Small G, Erkinjuntti T, Kurz A, Lilienfeld S. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. <i>CNS Drugs</i> 2003; 17 (12):905-14	Not a disease modification trial
Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. <i>Neurology</i> 1991; 41 (11):1726-32	Not a disease modification trial
Spector A, Orrell M, Woods B. Cognitive Stimulation Therapy (CST): effects on different areas of cognitive function for people with dementia. <i>International Journal of Geriatric Psychiatry</i> 2010; 25 (12):1253-8	Not a disease modification trial

Reference	Reason for exclusion
Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, et al. Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia. <i>The British Journal of Psychiatry</i> 2003; 183 (3):248-54	Not a disease modification trial
Spector A, Woods B, Orrell M. Cognitive stimulation for the treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> 2008; 8 (5):751-7	Not a disease modification trial
Spilich GJ, Wannemacher W, Duarte A, Buendia R, Gomez JT, Ramirez S, et al. Efficacy of pyritinol versus hydergine upon cognitive performance in patients with senile dementia of the Alzheimer's type: A double-blind multi-center trial. <i>Alzheimer's Research</i> 1996; 2 (3):79-84	Not a disease modification trial
Sramek JJ, Viereck C, Huff FJ, Wardle T, Hourani J, Stewart JA, et al. A ""bridging"" (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer's disease. <i>Life sciences</i> 1995; 57 (12):1241-8	Not a disease modification trial
Standridge JB. Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer's disease. <i>Evidence Based Mental Health</i> 2004; 7 (4):112- 1p	Not a disease modification trial
Steele LS, Glazier RH. Is donepezil effective for treating Alzheimer's disease? <i>Canadian family physician Médecin de famille canadien</i> 1999; 45 :917-9	Not a disease modification trial
Stein MS, Scherer SC, Ladd KS, Harrison LC. A randomized controlled trial high-dose vitamin D2 followed by intranasal insulin in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> 2011; 26 (3):477-84	Not a disease modification trial
Stein AM, Vital TM, Coelho FGM, Andrade LP, Pereira JR, Garuffi M, et al. Aerobic exercise training effect on cognitive functions, neuropsychiatric disorders, functionality, quality of life and lipid profile in elderly with Alzheimer's disease. <i>European Geriatric Medicine</i> 2014; 5 :105-6	Not published in a peer reviewed journal article or an ongoing trial
Stern Y, Sano M, Mayeux R Long-term administration of oral physostigmine in Alzheimer's disease. <i>Neurology</i> 1988; 38 (12):1837-41	Not a disease modification trial
Storey P HL, Duke L, Callaway R, & Marson D. Does chronic oral physostigmine alter the course of Alzheimer's disease? <i>Neurobiology of Aging</i> 1992; 13 (Suppl 1):126	Not published in a peer reviewed journal article or an ongoing trial
Stott DJ, MacIntosh G, Lowe GDO, Rumley A, McMahon AD, Langhorne P, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. <i>American Journal of Clinical Nutrition</i> 2005; 82 (6):1320-6	Not a disease modification trial
Streater A, Spector A, Aguirre E, Hoe J, Hoare Z, Woods R, et al. Maintenance Cognitive Stimulation Therapy (CST) in practice: study protocol for a randomized controlled trial. <i>Trials</i> 2012; 13 :91	Not a disease modification trial
Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. <i>BMJ open</i> 2014 1 ;4(7):e005158	Not a randomised controlled trial/clinical controlled trial

Reference	Reason for exclusion
Suh GH, Jung HY, Lee CU, Choi S, Korean Galantamine Study G. Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study. <i>Journal of Korean Medical Science</i> 2008; 23 (1):10-7	Not a disease modification trial
Suh GH, Jung HY, Lee CU, Lee SK, Lee NJ, Kim JH. [Effect of Galantamine on Caregiver Time and Activities of Daily Living in Mild to Moderate Alzheimer's Disease: A 1-Year Prospective Study]. <i>Journal of the Korean Geriatrics Society</i> 2007; 11 (2):74-82	Full text unavailable in English
Suh GH, Jung HY, Lee CU, Oh BH, Lee SK, Lee N, et al. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease. <i>Dementia & Geriatric Cognitive Disorders</i> 2006; 21 (1):33-9	Not a disease modification trial
Suh GH, Yeon Jung H, Uk Lee C, Hoon Oh B, Nam Bae J, Jung HY, et al. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. <i>Clinical Therapeutics</i> 2004; 26 (10):1608-18	Not a disease modification trial
Sun Y, Lu C-J, Chien K-L, Chen S-T, Chen R-C. Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: A 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. <i>Clinical Therapeutics: The International Peer-Reviewed Journal of Drug Therapy</i> 2007; 29 (10):2204-14	Not a disease modification trial
Suzuki T, Futami S, Igari Y, Matsumura N, Watanabe K, Nakano H, et al. A Chinese herbal medicine, choto-san, improves cognitive function and activities of daily living of patients with dementia: a double-blind, randomized, placebo-controlled study. <i>Journal of the American Geriatrics Society</i> 2005; 53 (12):2238-40	Not a disease modification trial
Tadaka E, Kanagawa K. A randomized controlled trial of a group care program for community-dwelling elderly people with dementia. <i>Japan Journal of Nursing Science</i> 2004; 1 (1):19-25	Not a disease modification trial
Tadaka E, Kanagawa K. Effects of reminiscence group in elderly people with Alzheimer disease and vascular dementia in a community setting. <i>Geriatrics & Gerontology International</i> 2007; 7 (2):167-73	Not a disease modification trial
Tajadini H, Saifadini R, Choopani R, Mehrabani M, Kamalinejad M, Haghdoost AA. Herbal medicine Davaie Loban in mild to moderate Alzheimer's disease: A 12-week randomized double-blind placebo-controlled clinical trial <i>Complementary Therapies in Medicine</i> 2015; 23 (6):767-72	Not a disease modification trial
Takahashi T, Matsushita H. Long-term effects of music therapy on elderly with moderate/severe dementia. <i>Journal of Music Therapy</i> 2006; 43 (4):317-33	Not a disease modification trial
Tariot P, Sabbagh M, Flitman S, Reyes P, Taber I, Seely L. A safety, tolerability and pharmacokinetic study of dimebon in patients with Alzheimer's disease already receiving donepezil. <i>Alzheimer's & Dementia</i> 2009; 5 :251	Not published in a peer reviewed journal article or an ongoing trial

Reference	Reason for exclusion
Tariot P, Salloway S, Yardley J, Mackell J, Moline M. Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease. <i>BMC Research Notes</i> 2012; 5 :283	Not a disease modification trial
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. <i>Jama</i> 2004; 291 (3):317-24	Not a disease modification trial
Tariot PN, Goldstein B, Podgorski CA, Cox C, Frambes N. Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type. <i>American journal of geriatric psychiatry</i> 1998; 6 (2):145-54	Not a disease modification trial
Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. <i>Neurology</i> 2000; 54 (12):2269-76	Not a disease modification trial
Tarraga L, Boada M, Modinos G, Espinosa A, Diego S, Morera A, et al. A randomised pilot study to assess the efficacy of an interactive, multimedia tool of cognitive stimulation in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> 2006; 77 (10):1116-21	Not a disease modification trial
Teipel SJ, Drzezga A, Bartenstein P, Moller HJ, Schwaiger M, Hampel H. Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer's disease: A double-blind cross-over trial. <i>Psychopharmacology</i> 2006; 187 (1):86-94	Not a disease modification trial
Thai LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. <i>Neurology</i> 1996; 47 (3):705-11	Not a disease modification trial
Thal L, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. <i>Neurology</i> 2003; 61 (11):1498-502	Not a disease modification trial
Thal LJ, Calvani M, Amato A, Carta A. A 1-year controlled trial of acetyl-L-carnitine in early-onset AD. <i>Neurology</i> 2000; 55 (6):805-10	Not a disease modification trial
Thal LJ, Ferguson JM, Mintzer J, Raskin A, Targum SD. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. <i>Neurology</i> 1999; 52 (6):1146-52	Not a disease modification trial
Thal LJ, Forrest M, Loft H, Mengel H. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group. <i>Neurology</i> 2000; 54 (2):421-6	Not a disease modification trial
Thal LJ, Fuld PA, Masur DM, Sharpless NS. Oral physostigmine and lecithin improve memory in Alzheimer disease. <i>Annals of neurology</i> 1983; 13 (5):491-6	Not a disease modification trial
Thal LJ, Masur DM, Sharpless NS. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> 1986; 10 (3-5):627-36	Not a disease modification trial
Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, et al. A multicenter double-blind study of controlled-release physostigmine for the	Not a disease modification trial

Reference**Reason for exclusion**

treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group. *Neurology* 1996;**47**(6):1389-95

Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. *International Journal of Geriatric Psychiatry* 2005;**20**(10):938-44

Not a disease modification trial

Thompson ITL, Filley CM, Mitchell WD, Culig KM, LoVerde M, Byyny RL. Lack of efficacy of hydergine in patients with Alzheimer's disease. *N Engl J Med* 1990;**323**(7):445-8

Not a disease modification trial

Tian J, Shi J, Miao Y, Wei M. Efficacy and safety of an herbal therapy in patients with early stage of Alzheimer's disease: A 24-week randomized phase III trial. *Alzheimers Dement* 2011;**1**:790

Not a disease modification trial

Tian J, Shi J, Wei M, Qin R, Chen Y, Wang Y. Efficacy and safety of ffd tablets in people with mild-to-moderate vascular dementia: A 24-week randomized, doubleblind, placebo, parallel-controlled trial. *Alzheimers Dement* 2013;**1**:670-1.

Not published in a peer reviewed journal article or an ongoing trial

Tinklenberg JR, Kraemer HC, Yaffe K, Ross L, Sheikh J, Ashford JW, et al. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice? *American Journal of Geriatric Psychiatry* 2007;**15**(11):953-60

Not a disease modification trial

Tocco M, Hendrix S, Miller M, Pejovic V, Graham S. Effects of extended-release memantine (28 MG/DAY) on activities of daily living in patients with moderate to severe Alzheimer's disease: Post hoc factor analysis of a randomized trial. *Alzheimers Dement* 2011;**1**:790-1

Not published in a peer reviewed journal article or an ongoing trial

Tocco M, Hendrix S, Miller M, Pejovic V, Graham S. Effects of extended-release memantine (28 MG/day) on cognitive domains in patients with moderate to severe Alzheimer's disease: Post hoc analysis of a randomized trial. *Alzheimers Dement* 2011;**1**:784-5

Not published in a peer reviewed journal article or an ongoing trial

Tocco M, Hendrix S, Miller M, Pejovic V, Graham S. Clinical benefits of extended-release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: Post hoc analysis from a randomized trial. *Alzheimers Dement* 2013;**1**:655

Not published in a peer reviewed journal article or an ongoing trial

Tocco M, Hendrix S, Miller ML, Pejovic V, Graham SM. Effects of extended-release memantine (28 mg, once daily) on language and communication abilities in patients with moderate to severe Alzheimer's disease. *Annals of Neurology* 2012;**72**:S52-S3.

Not published in a peer reviewed journal article or an ongoing trial

Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. *Biological psychiatry* 1990;**27**(10):1133-42

Not a disease modification trial

Trollor JN SP, Haindl W, Brodaty H, Wen W, Walker BM. Combined cerebral blood flow effects of a cholinergic agonist (milameline) and a verbal recognition task in early Alzheimer's disease. *Psychiatry & Clinical Neurosciences* 2006;**60**(15):616-25

Not a disease modification trial

Reference	Reason for exclusion
Tsai GE, Falk WE, Gunther J. A preliminary study of D-cycloserine treatment in Alzheimer's disease. <i>Journal of neuropsychiatry and clinical neurosciences</i> 1998; 10 (2):224-6	Not a disease modification trial
Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, et al. A multi-center randomized proof-of-concept clinical trial applying [18F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> 2010; 22 (4):1241-56	Not a disease modification trial
Van de Winckel A, Fey H, De Weerd W, Dom R. Cognitive and behavioural effects of music-based exercises in patients with dementia. <i>Clinical Rehabilitation</i> 2004; 18 (3):253-60	Not a disease modification trial
van Dongen M, van Rossum E, Kessels A, Sielhorst H, Knipschild P. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. <i>Journal of Clinical Epidemiology</i> 2003; 56 (4):367-76	Not a disease modification trial
Van Dyck CH, Lin CH, Robinson R, Cellar J, Smith EO, Nelson JC, et al. The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease. <i>Psychopharmacology</i> 1997; 132 (3):217-26	Not a disease modification trial
van Dyck CH, Newhouse P, Falk WE, Mattes JA. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group <i>Archives of General Psychiatry</i> 2000; 57 (2):157-64	Not a disease modification trial
van Dyck CH, Tariot PN, Meyers B, Resnick E. A 24-week randomized, controlled trial of memantine in patient with moderate-to-severe Alzheimer disease. <i>Alzheimer Disease and Associated Disorders</i> 2007; 21 (2):136-43	Not a disease modification trial
Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. <i>Neuroreport</i> 2002; 13 (1):83-7	Not a disease modification trial
Vereschagin NV NY, Lebedeva NV, Suslina ZA, Solovyev OI, Piradov MA, et al. [Mild forms of multiinfarct dementia - effectiveness of Cerebrolysin]. <i>Sovetskaya Meditsina</i> 1991; 11 :6-8	Full text unavailable in English
Veroff AE, Bodick NC, Offen WW, Sramek JJ, Cutler NR. Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). <i>Alzheimer disease and associated disorders</i> 1998; 12 (4):304-12	Not a disease modification trial
Villardita C, Grioli S, Lomeo C, Cattaneo C, Parini J. Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree. <i>Neuropsychobiology</i> 1992; 25 (1):24-8	Not a disease modification trial
Villardita C, Parini J, Grioli S, Quattropani M, Lomeo C, Scapagnini U. Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia. <i>Journal of Neural Transmission Supplementum</i> 1987; 24 :293-8	Not a disease modification trial
Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Pejoska S, et al. A 52-week pilot study targeting abeta with PBT2: Neuroimaging results. <i>Neurodegenerative Diseases</i> 2015; 15 :308	Not published in a peer reviewed journal article or an ongoing trial

Reference	Reason for exclusion
Viola LF, Nunes PV, Yassuda MS, Aprahamian I, Santos FS, Santos GD, et al. Effects of a multidisciplinary cognitive rehabilitation program for patients with mild Alzheimer's disease. <i>Clinics</i> 2011; 66 (8):1395-400	Not a disease modification trial
Vreugdenhil A, Cannell J, Davies A, Razay G. A community-based exercise programme to improve functional ability in people with Alzheimer's disease: a randomized controlled trial. <i>Scandinavian Journal of Caring Sciences</i> 2012; 26 (1):12-9	Not a disease modification trial
Wade AG, Farmer M, Harari G, Fund N, Laudon M, Nir T, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: A 6-month, randomized, placebo-controlled, multicenter trial. <i>Clinical interventions in aging</i> 2014; 9 :947-61	Not a disease modification trial
Waldemar G, Hoffmann K, Sobol N, Frederiksen K, Beyer N, Vogel A, et al. Effect of moderate-to-high intensity endurance exercise in elderly community-dwelling persons with mild-moderate Alzheimer's disease. <i>European Journal of Neurology</i> 2015; 22 :95.	Not published in a peer reviewed journal article or an ongoing trial
Walzl M, Walzl B, Kleinert G, Schied G, Lechner H. [Heparin-induced extracorporeal LDL precipitation (HELP). A new therapeutic possibility in cerebral multi-infarct dementia]. <i>Der Nervenarzt</i> 1993; 64 (10):648-52	Full text unavailable in English
Wang P, Yang J, Liu G, Chen H, Yang F. [Effects of moxibustion at head-points on levels of somatostatin and arginine vasopressin from cerebrospinal fluid in patients with vascular dementia: a randomized controlled trial]. <i>Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine</i> 2010; 8 (7):636-40	Full text unavailable in English
Wang PN, Liao SQ, Liu RS, Liu CY, Chao HT, Lu SR, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. <i>Neurology</i> 2000; 54 (11):2061-6	Not a disease modification trial
Warner J. Donepezil is more effective than galantamine for mild to moderate Alzheimer's disease. <i>Evidence Based Mental Health</i> 2004; 7 (3):77	Not published in a peer reviewed journal article or an ongoing trial
Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. <i>Jama</i> 1994; 271 (13):992-8	Not a disease modification trial
Wattmo C, Wallin AK, Londos E, Minthon L. Predictors of long-term cognitive outcome in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> 2011; 3 (4)	Not a disease modification trial
Wei MQ, Tian JZ, Shi J, Ma FY, Miao YC, Wang YY. Effects of Chinese medicine for promoting blood circulation and removing blood stasis in treating patients with mild to moderate vascular dementia: a randomized, double-blind and parallel-controlled trial. <i>Zhong Xi Yi Jie He Xue Bao/Journal of Chinese Integrative Medicine</i> 2012; 10 (11):1240-6	Not a disease modification trial
Weiner MF, Bonte FJ, Tintner R, Ford N, Svetlik D, Riall T. ACE inhibitor lacks acute effect on cognition or brain blood flow in Alzheimer's disease. <i>Drug Development Research</i> 1992; 26 (4):467-71	Not a disease modification trial

Reference	Reason for exclusion
Weinstein HC, Teunisse S, van Gool WA. Tetrahydroaminoacridine and lecithin in the treatment of Alzheimer's disease. Effect on cognition, functioning in daily life, behavioural disturbances and burden experienced by the carers. <i>Journal of Neurology</i> 1991; 238 (1):34-8	Not a disease modification trial
Wesnes KA, Aarsland D, Ballard C, Londos E. Improvements to attention and verbal episodic memory with memantine in Parkinson's disease dementia and dementia with lewy bodies. <i>Journal of Nutrition, Health and Aging</i> 2013; 17 (9):781-2	Not published in a peer reviewed journal article or an ongoing trial
Wesnes K, Aarsland D, Ballard C, Londos E. Memantine improves attention and verbal episodic memory in parkinson's disease dementia and dementiawith lewy bodies: A double-blind, placebo-controlled multicentre trial. <i>Alzheimers Dement</i> 2013; 1 :890	Not a disease modification trial
Wesnes KA, McKeith IG, Ferrara R, Emre M, Ser T, Spano PF, et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. <i>Dementia and geriatric cognitive disorders</i> 2002; 13 (3):183-92	Not a disease modification trial
Weyer G, Babej-Dölle RM, Hadler D, Hofmann S, Herrmann WM. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. <i>Neuropsychobiology</i> 1997; 36 (2):73-82	Not a disease modification trial
Weyer G, Erzigkeit H, Hadler D, Kubicki S. Efficacy and safety of idebenone in the long-term treatment of Alzheimer's disease: A double-blind, placebo controlled multicentre study. <i>Human Psychopharmacology</i> 1996; 11 (1):53-65	Not a disease modification trial
Weyer G, Eul A, Milde K, Wierich W, Herrmann WM. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study. <i>Pharmacopsychiatry</i> 2000; 33 (3):89-97	Not a disease modification trial
White HK, Levin ED. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. <i>Psychopharmacology</i> 1999; 143 (2):158-65	Not a disease modification trial
Wiegers RL, Kamphuis P, Stam C, Shah R, Bennett D, Hartmann T, et al. An overview of the medical food souvenaid clinical trial program. <i>Alzheimer's & dementia</i> 2013; 9 (4 suppl. 1):669	Not a disease modification trial
Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, et al. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. <i>Drugs & aging</i> 2003; 20 (10):777-89	Not a disease modification trial
Wilcock G, Möbius HJ, Stöffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). <i>International clinical psychopharmacology</i> 2002; 17 (6):297-305	Not a disease modification trial
Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. <i>BMJ British Medical Journal</i> 2000; 321 (7274):1445-9	Not a disease modification trial

Reference	Reason for exclusion
Wilcock GK, Surmon DJ, Scott M, Boyle M, Mulligan K, Neubauer KA, et al. An evaluation of the efficacy and safety of tetrahydroaminoacridine (THA) without lecithin in the treatment of Alzheimer's disease. <i>Age and ageing</i> 1993; 22 (5):316-24	Not a disease modification trial
Wilkinson D, Colding-Jorgensen E, Windfeld K. A clinical phase II study of LU AE58054 added to stable donepezil treatment in patients with moderate Alzheimer's disease. <i>Alzheimer's & dementia</i> 2013; 9 (4 suppl. 1):P529	Not published in a peer reviewed journal article or an ongoing trial
Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil in vascular dementia: A randomized, placebo-controlled study. <i>Neurology</i> 2003; 61 (4):479-86	Not a disease modification trial
Wilkinson D, Fox NC, Barkhof F, Phul R, Lemming O, Scheltens P. Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial. <i>Journal of Alzheimer's disease</i> 2012; 29 (2):459-69	Not a disease modification trial
Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. <i>International journal of geriatric psychiatry</i> 2001; 16 (9):852-7	Not a disease modification trial
Wilkinson D, Róman G, Salloway S, Hecker J, Boundy K, Kumar D, et al. The long-term efficacy and tolerability of donepezil in patients with vascular dementia. <i>International Journal of Geriatric Psychiatry</i> 2010; 25 (3):305-13	Not a disease modification trial
Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. <i>International Journal of Clinical Practice</i> 2002; 56 (6):441-6	Not a disease modification trial
Willan AR, Goeree R, Pullenayegum EM, McBurney C, Blackhouse G. Economic evaluation of rivastigmine in patients with Parkinson's disease dementia. <i>Pharmacoeconomics</i> 2006; 24 (1):93-106	Not a disease modification trial
Wimo A, Gaudig M, Schauble B, Jedenius E. The economic impact of galantamine vs placebo: an analysis based on functional capacity in a Swedish cohort study. <i>Journal of Medical Economics</i> 2012; 15 (5):1019-24	Not a disease modification trial
Wimo A, Winblad B, Shah SN, Chin W, Zhang R, McRae T. Impact of donepezil treatment for Alzheimer's disease on caregiver time. <i>Current medical research and opinion</i> 2004; 20 (8):1221-5	Not a disease modification trial
Wimo A, Winblad B, Soininen H, Verhey F, Waldemar G, Wetterholm AL, et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: Results of a 1-year, double-blind, randomized trial. <i>Dementia and Geriatric Cognitive Disorders</i> 2003; 15 (1):44-54	Not a disease modification trial
Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. <i>Neurology</i> 2001; 57 (3):489-95	Not a disease modification trial
Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, et al. Phenserine efficacy in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> 2010; 22 (4):1201-8	Not a disease modification trial

Reference	Reason for exclusion
Winblad B, Grossberg G, Frolich L, Farlow M, Zechner S, Nagel J, et al. A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. <i>Neurology</i> 2007; 69 (4,Suppl1):14-22	Not a disease modification trial
Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. <i>Dementia and geriatric cognitive disorders</i> 2006; 21 (5-6):353-63	Not a disease modification trial
Wirth Y, Rive B. Memantine enhances autonomy in moderate to severe Alzheimer's disease patients already receiving donepezil. <i>European Journal of Neurology</i> 2012; 19 :474	Not a disease modification trial
Wolters E, Riekkinen P, Lowenthal A, Van der Plaats J, Zwart J, Sennel C. DGAVP (Org 5667) in early Alzheimer's disease patients: An international double-blind, placebo-controlled, multicenter trial. <i>Neurology</i> 1990; 40 (7):1099-101	Not a disease modification trial
Wong WJ, Liu HC, Fuh JL, Wang SJ, Hsu LC, Wang PN, et al. A double-blind, placebo-controlled study of tacrine in Chinese patients with Alzheimer's disease. <i>Dementia and geriatric cognitive disorders</i> 1999; 10 (4):289-94	Not a disease modification trial
Woods B, Thorgrimsen L, Spector A, Royan L, Orrell M. Improved quality of life and cognitive stimulation therapy in dementia. <i>Aging & mental health</i> 2006; 10 (3):219-26	Not a disease modification trial
Wouters CJ, Dautzenberg L, Thissen A, Dautzenberg PL. [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands]. <i>Tijdschrift voor gerontologie en geriatrie</i> 2010; 41 (3):146-50	Full text unavailable in English
Xiao S, Wang T, Huang Q, Chen K, Reiman E. Changes of biological markers and brain pet imaging and clinical effects of memantine for patients with moderate to severe Alzheimer's disease: A 24 week double-blind, randomized, placebo-controlled study. <i>Journal of Nutrition, Health and Aging</i> 2012; 16 (9):855.	Not published in a peer reviewed journal article or an ongoing trial
Xiao S, Yan H, Yao P. The efficacy of cerebrolysin in patients with vascular dementia: results of a Chinese multicentre, randomised, double-blind, placebo-controlled trial. The Cerebrolysin Study Group. <i>Hong Kong J Psychiatry</i> 1999; 9 (2):13-9.	Unable to find a copy of the full text
Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. <i>Zhongguo yao li xue bao (Acta pharmacologica Sinica)</i> 1995; 16 (5):391-5	Not a disease modification trial
Xue SW, Ding JM, Zhong P, Liang K, An HY, Bo Y. Impacts of huperzine A on the level of Fas, Apo2.7 and Bcl-2 on the platelet membrane and the cognitive function in patients with Alzheimer disease. <i>Chinese Journal of Clinical Rehabilitation</i> 2005; 9 (9):188-9	Full text unavailable in English
Yamanaka K, Kawano Y, Noguchi D, Nakaaki S, Watanabe N, Amano T, et al. Effects of cognitive stimulation therapy Japanese version (CST-J) for people with dementia: A single-blind, controlled clinical trial. <i>Aging & Mental Health</i> 2013; 17 (5):579-86	Not a disease modification trial

Reference	Reason for exclusion
Yan YX, Liang LZ, Zhou ZL. Clinical study of combined treatment with compound Reinhartdt and Sea Cumber Capsule and donepezil for vascular dementia. <i>Zhongguo Zhong xi yi jie he za zhi (Chinese journal of integrated traditional and Western medicine)</i> 2007; 27 (10):887-90	Full text unavailable in English
Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke S, Hoerr R, et al. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial <i>Aging & Mental Health</i> 2009; 13 (2):183-90	Not a disease modification trial
Yoo HB, Choi JS, Yoon EJ, Lee HY, Kim YK, Lee H, et al. Efficacy of cilostazol augmentation treatment in Alzheimer's disease with white matter lesion by FDG PET. <i>International Psychogeriatrics</i> 2013; 25 :S58	Not published in a peer reviewed journal article or an ongoing trial
Yoon BK, Kim DK, Kang Y, Kim JW, Shin MH, Na DL. Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study. <i>Fertility and sterility</i> 2003; 79 (2):274-80	Not a disease modification trial
Yu F, Bronas U, Nelson N, Dysken M, Jack C, Konety S, et al. Aerobic exercise in Alzheimer's disease: The FIT-AD trial. <i>Alzheimer's & dementia</i> 2014; 10 :851-2	Not a disease modification trial
Yu F, Bronas UG, Konety S, Nelson NW, Dysken M, Jack Jr C, et al. Effects of aerobic exercise on cognition and hippocampal volume in Alzheimer's disease: study protocol of a randomized controlled trial (The FIT-AD trial). <i>Trials</i> 2014; 15 (1):394	Not a disease modification trial
Yu J, Zhang X, Liu C, Meng Y, Han J. Effect of acupuncture treatment on vascular dementia. <i>Neurological Research</i> 2006; 28 (1):97-103	Not a disease modification trial
Yu L, Lin SM, Zhou RQ, Tang WJ, Huang PX, Dong Y, et al. Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: A randomized controlled trial. <i>Journal of Chinese Integrative Medicine</i> 2012; 10 (7):766-76	Full text unavailable in English
Zamfirescu A, Capisizu A, Slavila M, Capisizu AA, Romila A. Physical exercise training in older adults diagnosed with mild to moderate dementia. <i>Journal of Nutrition, Health and Aging</i> 2012; 16 (9):861-2	Not published in a peer reviewed journal article or an ongoing trial
Zanetti O, Frisoni GB, De Leo D, Dello Buono M, Bianchetti A, Trabucchi M. Reality orientation therapy in Alzheimer disease: useful or not? A controlled study. <i>Alzheimer Disease & Associated Disorders</i> 1995; 9 (3):132-8	Not a disease modification trial
Zemlan FP, Keys M, Richter RW, Strub RL. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease. <i>Life sciences</i> 1996; 58 (21):1823-32	Not a disease modification trial
Zhang FR. Observation of Chinese herb kangnaoling in improving cognitive and daily living ability of patients with vascular dementia. <i>Chinese Journal of Clinical Rehabilitation</i> 2006; 10 (3):161-3	Full text unavailable in English
Zhang MZ, Dong ZX, Mao YJ, Du F. Effect of yizhi capsule on the intelligence of patient with multi-infarct dementia. <i>Chinese Journal of Clinical Rehabilitation</i> 2005; 9 (36):155-7.	Full text unavailable in English

Reference	Reason for exclusion
Zhang Y, Lin C, Zhang L, Cui Y, Gu Y, Guo J, et al. Cognitive Improvement during Treatment for Mild Alzheimer's Disease with a Chinese Herbal Formula: A Randomized Controlled Trial. <i>PLoS ONE</i> 2015; 10 (6):e0130353	Not a disease modification trial
Zhang YX, Luo G, Guo ZJ, Cui RY, Wang LQ, Zhou CL. Quantitative evaluation of the interventional effect of estrogen on Alzheimer disease. <i>Chinese Journal of Clinical Rehabilitation</i> 2006; 10 (30):37-9	Full text unavailable in English
Zhang YY, Yang LQ, Guo LM. Effect of phosphatidylserine on memory in patients and rats with Alzheimer's disease. <i>Genetics and molecular research</i> 2015; 14 (3):9325-33	Not a disease modification trial
Zhou BR XZ, Kuang YF, Deng YH, Liu ZF. Effectiveness of polydrug therapy for senile dementia. <i>Chinese Journal of Clinical Rehabilitation</i> 2004; 8 :1214	Full text unavailable in English
Zhu M, Xiao S, Li G, Li X, Tang M, Yang S, et al. Effectiveness and safety of generic memantine hydrochloride manufactured in China in the treatment of moderate to severe Alzheimer's disease: a multicenter, double-blind randomized controlled trial. <i>Shanghai Jingshen Yixue</i> 2013; 25 (4):244-53	Not a disease modification trial
Zieschang T, Schwenk M, Oster P, Hauer K. Long-term effect of a standardized motor training on cognition in patients with dementia: Results of a RCT. <i>European Geriatric Medicine</i> 2013; 4 :S211	Not published in a peer reviewed journal article or an ongoing trial